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PHT1	 (SLC15A4)	 is	 responsible	 for	 translocating	 L-histidine	 (L-His),	
di/tripeptides	and	peptide-like	drugs	across	biological	membranes.	Previous	studies	
have	 indicated	 that	 PHT1	 is	 located	 in	 brain	 parenchyma,	 however,	 its	 role	 and	
significance	 in	 brain,	 along	with	 its	 impact	 on	 the	 biodistribution	 of	 substrates	 is	
unknown.	 In	 the	 present	 study,	 adult	 gender-matched	Pht1-competent	 (wildtype)	
and	Pht1-deficient	(null)	mice	were	used	to	investigate	the	effect	of	PHT1	on	L-His	
brain	 disposition	 via	 in	vitro	 slice	 and	 in	vivo	 pharmacokinetic	 approaches.	 Initial	
phenotyping	 of	 the	 two	 genotypes	 and	 expression	 measurements	 of	 select	
transporters/enzymes	 were	 also	 performed.	 No	 significant	 differences	 were	
observed	 between	 genotypes	 in	 serum	 chemistry,	 body	 weight,	 viability	 and	
fertility.	 Polymerase	 chain	 reaction	 (PCR)	 analyses	 indicated	 that	 Pept2	 had	 a	
compensatory	 up-regulation	 in	 Pht1	 null	 mice	 (about	 2-fold)	 as	 compared	 to	
wildtype	animals,	which	was	consistent	in	different	brain	regions	and	confirmed	by	
immunoblots.	The	uptake	of	L-His	was	reduced	in	brain	slices	by	50%	during	PHT1	
ablation.	 The	 L-amino	 acid	 transporters	 accounted	 for	 30%	 of	 the	 uptake,	 and	
passive	(other)	pathways	for	20%	of	the	uptake.	During	the	in	vivo	pharmacokinetic	
(PK)	studies,	plasma	concentration-time	profiles	of	L-His	were	comparable	between	
the	 two	 genotypes	 after	 intravenous	 administration.	 Still,	 biodistribution	 studies	
	 xv	
revealed	that,	when	sampled	5	min	after	dosing,	L-His	values	were	28–48%	lower	in	




mediated	 uptake	 into	 brain	 parenchyma,	 influx	 and	 efflux	 rate	 constants	 of	 L-His	
between	plasma,	brain	parenchyma	and	CSF	were	modeled	as	first-order	processes.	
Diffusion	 between	 brain	 parenchyma	 and	 CSF,	 CSF	 bulk	 flow	 and	 tissue	 volumes	
were	obtained	from	the	 literature.	The	disposition	kinetics	of	L-His	 in	plasma,	CSF	






uptake	 of	 L-His	 in	 brain,	 for	 the	 first	 time,	 under	 in	 vivo	 conditions.	 The	 results	
suggest	 that	PHT1	may	play	an	 important	 role	 in	histidine	 transport	 in	brain,	and	
resultant	 effects	on	histidine/histamine	homeostasis	 and	neuropeptide	 regulation.	












Peptide/histidine	 transporter	 1	 (PHT1),	 a	 member	 of	 the	 proton-coupled	
oligopeptide	 transporter	 (POT)	 superfamily,	 is	 an	 integral	membrane	protein	 that	
translocates	 various	 di-/tri-peptides,	 peptidomimetics	 and	 L-histidine	 across	 the	
biological	 membrane.	 Currently	 four	 members	 of	 the	 POT	 family	 have	 been	
identified	 in	 mammals,	 including	 PEPT1	 (SLC15A1),	 PEPT2	 (SLC15A2),	 PHT1	
(SLC15A4)	 and	 PHT2	 (SLC15A3)	 [1].	 Among	 them,	 the	 localization,	 expression,	
function	and	pharmacological	relevance	of	peptide	transporters	PEPT1	and	PEPT2	
were	most	extensively	studied.	However,	little	is	known	about	the	peptide/histidine	
transporters,	PHT1	and	PHT2	 [2].	Each	of	 the	 four	POT	 family	proteins	displays	a	
distinct	 pattern	 of	 tissue	 expression	 with	 specific	 physiological	 and	 pathological	
roles	[3].	PEPT1	is	primarily	expressed	in	the	small	intestine,	where	it	is	responsible	
for	 the	 absorption	 of	 di-/tri-peptides	 from	 dietary	 proteins	 and	 gastrointestinal	
secretions	[4,	5].	In	the	kidney,	PEPT1	is	located	in	S1	segments	whereas	PEPT2	is	
preferentially	 expressed	 in	 brush	 border	 membranes	 of	 the	 latter	 parts	 of	 the	
proximal	 tubule	 (S3	 segments)	 in	 kidney	 [6].	 Together,	 PEPT1	 and	PEPT2	 govern	
the	 efficient	 reabsorption	 of	 peptides/mimetics	 from	 the	 tubular	 fluid	 [7].	 PEPT2	
protein	 also	 has	 strong	 expression	 in	 choroid	 plexus	 and	 brain	 parenchyma,	 the	
level	 of	 which	 shows	 an	 age-dependent	 declining	 expression	 [8].	 PEPT2	 in	 brain	
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appears	 to	 regulate	 neuropeptides	 homeostasis	 and	 protect	 against	 neurotoxicity	
[9].	PHT1	proteins	are	found	in	brain	and	eye	[10,	11].	In	contrast	to	PEPT2,	PHT1	
has	 an	 age-dependent	 increasing	 expression	 in	 brain.	 The	 expression	 of	 PHT1	
increases	in	a	similar	manner	with	the	function	and	localization	progression	of	the	
histaminergic	system	[12-16].	Moreover,	PHT1	function	dominates	in	adult	rodents,	









functions,	 including	 the	 formation	 of	 myelin	 sheath,	 the	 detoxification	 of	 heavy	
metals,	the	manufacture	of	white	and	red	blood	cells,	and	others.	It	is	a	precursor	of	
histamine,	 carnosine,	 ergothioneine,	 and	 vitamin	 C	 [22].	 Studies	 on	 the	 PHT1-
mediated	 transport	 of	 L-histidine	 in	 brain	 would	 extend	 our	 understanding	 of	
neuropeptide	regulation,	histamine	homeostasis,	and	PHT1	as	a	potential	target	for	
drug	 delivery	 to	 neuronal	 and	 non-neuronal	 cells.	 In	 the	 central	 nervous	 system	
(CNS),	the	major	transporters	for	L-histidine	include	the	Na+-coupled	neutral	amino	
acid	 transporters	 (e.g.	 SNATs,	belong	 to	SLC38	 family)	 [23,	24],	 some	members	of	




Histamine	 is	 one	 of	 the	most	 important	metabolites	 of	 L-histidine,	 formed	
during	 catalysis	 by	 L-histidine	 decarboxylase	 (HDC).	 Significant	 changes	 in	 brain	
histamine	 levels	 have	 been	 observed	 in	 several	 neurological	 diseases,	 such	 as	




Pht1-deficient	 mice	 provide	 a	 powerful	 tool	 to	 investigate	 the	 role	 and	
relevance	 of	 PHT1	 in	 L-histidine	 disposition	 in	 brain,	 as	 well	 as	 histamine	 levels	
with	 or	without	 exogenous	 L-histidine	 being	 supplied.	We	 hypothesize	 that	 PHT1	





2) To	 investigate	 the	 importance	 of	 PHT1	 in	 affecting	 the	 in	 vivo	
pharmacokinetics	and	tissue	distribution	of	L-histidine	in	wildtype	and	Pht1	
null	mice	
3) To	 develop	 a	 pharmacokinetic	 model	 that	 accurately	 characterizes	 the	


































































































Proton-coupled	 oligopeptide	 transporters	 (POTs),	which	 also	 belong	 to	 the	
solute	 carrier	 protein	 (SLC15)	 family,	 are	 integral	 membrane	 proteins	 that	
translocate	 various	 di-/tri-peptides	 and	 peptidomimetics	 across	 the	 biological	
membrane.	 Currently	 four	 members	 in	 the	 POT	 family	 have	 been	 identified	 in	
mammals,	 including	 PEPT1	 (SLC15A1),	 PEPT2	 (SLC15A2),	 PHT1	 (SLC15A4)	 and	
PHT2	 (SLC15A3)	 [1].	 The	 first	 identified	 H+-coupled	 transporter	 of	 oligopeptides	
and	peptide-derived	antibiotics,	PEPT1,	was	cloned	 from	rabbit	 small	 intestine	 [2,	
3].	 Following	 that,	 PEPT2	was	 isolated	 from	 kidney	 by	 screening	 a	 human	 cDNA	
library	[4].	Then,	with	further	investigation	into	transporters	of	the	nervous	system,	
the	peptide/histidine	 transporters	 (PHT1/	PHT2)	were	 isolated	 from	rat	brain	 [5,	
6].	 Localization	 and	 functional	 characterization	 of	 PHT1	 and	 PHT2	 were	 done	 in	
Xenopus	 laevis	 oocytes,	 showing	 that	 they	 can	 also	 recognize	 L-histidine,	 unlike	
PEPT1	 and	 PEPT2	 [5,	 6].	 	 PEPT1	 and	 PEPT2	 share	 similar	 hydrophobic	 domains,	
with	about	51%	sequence	homology	[7,	8].	However,	the	protein	sequences	of	PHT1	
and	PHT2	show	weak	similarity	 to	PEPT1	and	PEPT2	(less	 than	26%)	 [8].	Among	
the	POTs,	the	localization,	expression,	function,	and	the	pharmaceutical	relevance	of	
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of	 12	 transmembrane	 helices	 (TMH	 or	 H),	 with	 the	 N-	 and	 C-termini	 facing	 the	
cytoplasm	(Figure	2-1)	[10,	11].	





acid	 identity	 [8].	Mouse	PHT1	has	85%	amino	acid	 identity	 to	 its	human	ortholog,	
while	 rat	 PHT1	 has	 89%	 amino	 acid	 identity	 to	 human	 [8].	 There	 is	 no	 large	
extracellular	loop	between	H9	and	H10	in	PHT1.		
The	relationship	between	protein	regions	and	their	functional	characteristics	
showed	 different	 organizations	 on	 PEPT1	 and	 PEPT2.	 Much	 of	 the	 transport	
mechanism	 of	 these	 proteins,	 as	 well	 as	 their	 3-D	 structure,	 is	 inferred	 from	
chimeras	combining,	model	predictions	and	molecular	modeling	[11-13].	Basically,	
peptide/mimetic	substrates	are	 transported	through	a	central	pore,	where	several	
key	 residues	 face	 this	 transmembrane	 channel	 for	 peptide	 binding	 [14,	 15],	 and	
proton	binding	[16].	The	role	of	the	extracellular	loop	connecting	H9	and	H10	is	still	
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which	 include	 the	 E.coli	 proton-coupled	 lactose	 permease	 (LacY),	 the	 glycerol-3-
phosphate/inorganic	 phosphate	 antiporter	 (GlpT)	 and	 the	 multidrug	 transporter	
EmrD	 [2,	 10,	 18].	 As	 a	 result	 the	 crystal	 structures	 for	 them	 could	 be	 a	 good	
reference	 for	 the	 3-D	 structure	 of	 12-TM	 transporters.	 The	 3-D	 structure	 of	 a	
prokaryotic	 homologue	 of	 mammalian	 PEPT,	 PEPTso,	 was	 recently	 confirmed	
(Figure	 2-2)	 [18,	 19].	 PEPTso	 consists	 of	 the	 central	 and	 extracellular	 cavities.	





PEPT1	 and	 PEPT2	 proteins	may	mediate	 the	 transport	 of	 all	 400	 different	
dipeptides	 and	 8000	 different	 tripeptides	 from	 the	 20	 L-α-amino-acids	 in	 a	
sequence	independent	manner	[1].	However,	the	peptide	bond	is	not	a	prerequisite	
for	 transport	 since	 some	 omega-amino	 fatty	 acids	 (e.g.	 delta-aminolevulinic	 acid)	
are	 also	 substrates	 of	 PEPT1	 and	PEPT2	 [9,	 20].	With	 respect	 to	 pharmacological	
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relevance,	PEPT1	and	PEPT2	can	also	transport	a	variety	of	peptide-like	drugs	(e.g.	
cefadroxil,	 enalapril,	 valacyclovir),	 aminocephalosporins,	 angiotensin-converting	
enzyme	 inhibitors	 (ACE	 inhibitors)	 and	 others	 [11,	 21].	 Specifically,	 PEPT1	 is	 a	
“high-capacity,	 low-affinity”	 transporter,	 while	 PEPT2	 is	 a	 “low-capacity,	 high-
affinity”	 transporter.	 Substrate	 affinity	 is	 also	 determined	 by	membrane	 potential	
and	 external	 pH,	 where	 lower	 external	 pH	 values	 are	 favored	 for	 transport	 of	
negatively	 charged	 dipeptides,	 higher	 pH	 values	 increase	 the	 uptake	 rate	 of	




an	 optimal	 pH	 at	 pH	5.5	 [5],	 or	 pH	5.0	 [23].	More	 detailed	 information	 about	 the	
substrate	specificity	of	PHT	proteins	is	not	yet	available.		
The	 driving	 force	 of	 substrate	 uptake	 for	 POTs	 is	 an	 inwardly	 directed	 H+	
gradient	 (Figure	 2-3).	 It	 was	 confirmed	 that	 there	 is	 an	 acid	microclimate	 at	 the	
intervillous	space	of	jejunum	(pH	value	is	6.1-6.6)	related	to	H+	secretion,	while	the	
intracellular	 pH	 of	 enterocytes	 is	 7.3	 [24].	 	 Na+/H+	 antiporter	 activity	 could	 drive	








Many	 studies	 have	 demonstrated	 that	 PEPT1	 is	 primarily	 expressed	 in	 the	





3-5	 days	 after	 birth,	 decreased	 slowly,	 and	 then	 rose	 to	 59-88%	 of	 maximal	
expression	 at	 day	 24	 [33,	 34].	 In	 adult	 animals,	 small	 intestine	 PEPT1	 level	 is	 up	
regulated	 on	 high-protein	 diet,	 fast	 state,	 as	well	 as	 some	 pathological	 conditions	
(e.g.	inflammation)	[35-37].	
In	 colon,	 the	 expression	 of	 PEPT1	 is	 controversial.	 It	 was	 once	 considered	
that	 PEPT1	was	 neither	 expressed	 nor	 functioning	 in	 normal	 proximal	 and	 distal	
colon	 [28,	 29].	 However,	 the	 Daniel	 group	 recently	 reported	 that	 PEPT1	 was	
expressed	 in	 the	distal	 colon	of	normal	mouse,	 rat	 and	human.	According	 to	 their	
studies,	 colonic	 expression	 of	 PEPT1	 contributed	 to	 water	 absorption.	 Moreover,	
PEPT1	 was	 down	 regulated	 under	 conditions	 of	 acute	 and	 chronic	 intestinal	
inflammation	[38,	39].		
In	the	kidney,	PEPT1	is	found	in	brush	border	membranes	of	the	early	parts	





PEPT2	 is	 preferentially	 expressed	 in	 brush	 border	membrane	 of	 the	 latter	
parts	 of	 the	 proximal	 tubule	 (S3	 segments)	 in	 kidney	 [40].	 Together	with	 PEPT1,	
they	 are	 responsible	 for	 the	 reabsorption	 of	 peptides/mimetics	 from	 the	 tubular	
fluid	[44].	In	brain,	PEPT2	protein	is	strongly	expressed	in	cerebral	cortex,	olfactory	
bulb,	basal	ganglia,	 cerebellum,	hindbrain	and	 the	apical	 surface	of	choroid	plexus	
epithelia.	In	neonate	rat,	PEPT2	was	detected	in	both	astrocytes	and	neurons,	while	
in	adult	rat	PEPT2	was	only	detected	in	neurons.	The	expression	levels	declined	in	
an	 age-dependent	 manner	 [45].	 PEPT2	 functions	 in	 brain	 by	 regulating	
neuropeptides	homeostasis	and	by	protecting	 the	brain	against	neurotoxicity.	 It	 is	





is	 much	 less	 clear.	 PHT1	 and	 PHT2	 mRNA	 were	 found	 in	 several	 regions	 of	 the	
human	and	rat	gastrointestinal	tract	(GIT),	as	well	as	the	Caco-2	cell	model	[48].	As	
determined	by	 immunohistochemical	 analyses,	 PHT1	was	 expressed	 in	 the	villous	
epithelium	 along	 human	 small	 intestine	 [23],	 however,	 its	 relevance	 in	 substrate	
absorption	was	unclear.	PHT1	proteins	are	also	found	in	the	brain	and	eye	[5,	6].	A	
recent	 study	 showed	 that	 PHT1	 has	 an	 age-dependent	 increasing	 expression	 in	
brain,	 in	 contrast	 to	 that	 of	 PEPT2	 [49].	 The	 ascending	 level	 of	 PHT1	 occurs	 in	 a	
similar	manner	with	the	function	and	localization	of	the	histaminergic	system	[50-
54].	 Specifically,	 the	 function	 of	 PHT1	 dominates	 in	 adult	 rodents,	 suggesting	 a	
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significant	 role	 in	 regulating	 both	 endogenous	 and	 exogenous	 L-histidine	 and	
peptides/mimetics	in	brain	[49].	In	the	immune	system,	PHT1	transcripts	are	found	
in	 plasmacytoid	 dendritic	 cells	 [55].	 Its	 protein	 expression	 is	 significantly	 up-
regulated	 in	 colonic	 biopsies	 from	 inflammatory	 bowel	 disease	 (IBD)	 patients,	
which	may	 contribute	 to	 the	 transport	 of	 Nod1	 ligands	 to	 the	 cytosol	 [56].	 PHT1	
transcripts	 are	 also	 detected	 in	 rat	 thyroid	 gland	 [57],	 and	 skeletal	 muscle	 [58].	
PHT2	mRNA	is	found	in	the	lung,	spleen	and	thymus	[6].		
Unlike	PEPT	proteins,	which	are	mainly	expressed	on	the	plasma	membrane,	
PHT	 proteins	 are	 expressed	 in	 the	 intracellular	 compartment.	 Subcellular	
localization	 studies	 show	 that	 PHT1	 co-localizes	 with	 endosome	 and	 lysosome	
markers,	 which	 may	 transport	 free	 histidine	 and	 oligopeptides	 from	 inside	 the	
endosome	 to	 the	cytosol	 [56,	59].	Rat	PHT2	protein	has	also	been	 localized	 to	 the	
lysosomal	membrane	 [6].	 A	 recent	 study	 showed	 that	 PHT1	 and	 PHT2	 are	 highly	
involved	 in	 the	 immune	 response.	 PHT1	 expressed	 in	 dendritic	 cells	 is	 intimately	
involved	 in	 the	 immunologic	 diseases	 related	 to	 TLR9	 stimulation,	 such	 as	 lupus,	
colitis	 and	 persistent	 viral	 infection	 [59-61].	 Recent	 genome-wide	 association	
studies	 on	 systemic	 lupus	 erythematosus	 identified	 PHT1	 variants	 as	 an	 Asian-
specific	locus	for	this	disease	[62-64].	
2.2	L-Histidine	transporters	in	brain	
Histidine	 is	 a	 basic	 and	 hydrophilic	 α-amino	 acid.	 The	 active	 isomer	 is	 L-
histidine	 (Figure	 2-4).	 It	 is	 one	 of	 the	 21	 proteinogenic	 amino	 acids	 essential	 for	
human	 health.	 It	 is	 obtained	 from	dietary,	metabolism	 and	 protein	 turnover	 [65].	
The	 imidazole	 functional	 group	 in	 histidine	 has	 a	 pKa	 of	 approximately	 6.0.	 The	
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imidazole	 aromatic	 ring	 is	 protonated	 and	 carries	 a	 positive	 charge	when	 the	 pH	
value	is	below	6.0,	which	can	serve	as	a	general	acid.	The	unprotonated	imidazole	is	
nucleophilic	and	can	serve	as	a	general	base	(Figure	2-4).	As	a	result,	L-histidine	is	a	
common	 participant	 in	 enzyme-catalyzed	 reactions.	 L-histidine	 is	 involved	 in	
several	biological	functions,	including	formation	of	the	myelin	sheath,	detoxification	
of	 heavy	metals,	manufacturing	white	 and	 red	 blood	 cells,	 and	 others.	 It	 is	 also	 a	
precursor	 for	 the	 synthesis	 of	 histamine,	 carnosine,	 ergothioneine,	 and	 vitamin	 C	








basement	membrane	 [68].	 The	 tight	 junctions	 among	 the	 adjacent	 cells	 form	 the	
barrier,	sealing	off	 the	paracellular	diffusion	space.	Thus,	 to	cross	the	BBB,	solutes	
have	to	partition	into	and	diffuse	through	the	cell	membrane,	or	be	transported	by	
carriers.	Despite	 the	highly	 reduced	 flux	 rate	across	 the	BBB,	brain	 capillaries	 are	
still	the	primary	site	of	exchange	for	most	solutes	between	the	brain	compartment	
and	blood	because	of	its	large	surface	area	[69].	Intensive	research	has	focused	on	
the	 transport	 of	 amino	 acids	 across	 the	 BBB.	 Many	 transporter	 systems	 were	





respectively)	 mediate	 the	 uptake	 of	 amino	 acids	 with	 large	 neutral	 side	 chains,	








abluminal	 side.	 Although	 considered	 Na+-independent	 transporters,	 they	 can	 also	
transport	neutral	 amino	acid	 substrates	 in	 a	Na+	dependent	manner	but	with	 low	
efficiency	[74].		
Unlike	 the	 Na+-independent	 transporters	 described	 previously,	 the	 Na+-
dependent	 transporters	 are	 expressed	 only	 in	 abluminal	 membranes	 [75].	 Na+-
dependent	 transporters	 possess	 the	 ability	 to	 transfer	 amino	 acids	 from	 brain	
extracellular	 fluid	 into	 endothelial	 cells	 with	 high	 affinity	 [76].	 Moreover,	 these	
carriers	are	able	to	efflux	substrates	from	the	extracellular	fluid	(ECF)	to	endothelial	
cells	 and,	 hence	 to	 the	 systemic	 circulation,	 utilizing	 the	 Na+-electrochemical	
potential	 gradient.	 This	 vectorial	 transport	 may	 explain	 the	 significantly	 lower	
concentrations	 of	 amino	 acids	 in	 brain	 ECF	 than	 in	 plasma	 [72].	 Na+-dependent	
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transporters	 can	 be	 inhibited	 by	 BCH	 and	 a	 wide	 range	 of	 amino	 acids.	 [75]	
According	to	current	research,	 the	Na+-dependent	 transporter	of	L-histidine	at	 the	
BBB	 includes	 the	 following:	 system	 A	 transporters	 SNAT1	 and	 SNAT2	 [77]	 and	
system	N	transporters	SNAT3	and	SNAT5	[78,	79],	of	which	all	belong	to	the	SLC38	
family;	 and	 the	 system	 B0,+	 transporter	 B0AT3	 (SLC6A17)	 [80].	 SLC38	 family	
proteins	will	be	discussed	in	more	detail	in	subsequent	sections.	




CSF	 barrier	 (BCSFB).	 The	 structural	 basis	 of	 the	 BCSFB	 consists	 of	 CP	 cuboidal	
epithelium	 cells,	which	 are	 also	 linked	 by	 tight	 junctions	 [81].	 However,	 the	 tight	
junctions	of	BCSFB	are	much	weaker	than	that	of	the	BBB,	making	CPs	belong	to	the	
class	of	 leaky	 epithelia	 [82].	 Several	 L-histidine	 transporter	 systems	expressed	on	
both	the	CPs	and	BBB	include	LAT1	[83],	LAT2,	SNAT3	[84],	and	Asc-1	(SLC7A10)	
[85].		
The	mRNA	of	PHT1	was	also	 identified	 in	CPs	 [5].	However,	PHT1	may	not	
contribute	to	the	transport	of	L-histidine	at	this	site,	as	the	uptake	of	L-histidine	into	
brain	 is	 not	 inhibited	 by	 dipeptides	 [86,	 87],	 nor	 is	 the	 transport	 of	 dipeptides	
inhibited	by	L-histidine	[88,	89].	
2.2.2	Transport	of	L-histidine	in	brain	parenchyma	
Although	 the	 brain	 barrier	 systems	 determine	 the	 concentration	 of	 amino	




metabolic	 substrates,	 neurotransmitters	 and	 neurotransmitter	 precursors,	
regulating	 the	 signaling	 pathway	 [90].	 The	 major	 amino	 acid	 transporters	 of	 L-
histidine	 in	 brain	 parenchyma	 include	 the	 Na+-coupled	 neutral	 amino	 acid	
transporters	 (e.g.,	 SNATs,	 which	 belong	 to	 the	 SLC38	 family)	 [91,	 92],	 Na+-
independent	amino	acid	transporters	(e.g.,	LATs	and	CATs,	which	belong	to	the	SLC7	





flux	 of	 amino	 acids	 in	 CNS	 [91,	 96].	 As	mentioned	 above,	 system	A	 and	 system	N	
transporters	 are	 the	 two	 major	 divisions	 of	 this	 protein	 family.	 System	 A	
transporters	 (SNAT1,	 2,	 4	 and	 8)	 are	 Na+	 dependent,	 having	 a	 classical	 inhibitor	
amino	 acid	 analogue	 2-methylamino-isobutyric	 acid	 (MeAIB).	 System	 N	
transporters	 (SNAT3,	 5	 and	 7)	 are	 Na+	 and	 H+	 dependent,	 having	 no	 MeAIB	
selectivity.	 However,	 the	 classification	 of	 SNATs	 is	 still	 controversial.	 Some	
transporters	 are	 more	 likely	 to	 be	 treated	 as	 the	 “orphan	 members”,	 such	 as	
SNAT7/8/10	 [97].	 The	 major	 physiological	 function	 of	 SNATs	 in	 the	 CNS	 is	 to	
transport	glutamine	 in	 the	glutamate/glutamine	cycle	 [98].	Affinity	of	SNATs	 to	L-
histidine	 is	 relatively	 low,	 with	 Michaelis-Menten	 (Km)	 values	 in	 the	 millimolar	
range	[78,	79,	99].	
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SLC6	 family	 transporters	 are	also	known	as	neurotransmitter	 transporters.	
Several	SLC6	members	expressed	 in	synapses	are	 important	 in	neurotransmission	
termination	 and	 clearance	 [94].	 In	 this	 family,	 SLC6A15-encoded	B0AT2	 is	mainly	
expressed	 in	neurons	and	astrocytes	[95],	where	the	major	substrates	are	proline,	
methionine,	 isoleucine	 and	 leucine.	 Its	 affinity	 to	 L-histidine	 is	 low	 (millimolar	
values	 of	 Km)	 [100].	 NTT4	 (SLC6A17)	 is	 identified	 only	 in	 the	 nervous	 system,	
especially	 in	 synaptic	 vesicles,	 with	 a	 Km	 of	 1-2	mM	 for	 proline	 and	 glycine	 and	
interestingly	no	affinity	for	L-His	[43].	L-histidine	can	self-inhibit	its	transport,	while	





had	 an	 age-dependent	 increase	 in	 brain	 expression,	 in	 contrast	 to	 PEPT2	 which	
decreased	over	time.	The	increasing	expression	of	PHT1	from	neonate	to	adult	age	
was	similar	to	the	function	and	localization	progression	of	the	histaminergic	system	
[50-54].	Moreover,	 the	 function	of	PHT1	dominated	 in	adult	 rodents,	 suggesting	a	
significant	 role	 in	 regulating	 both	 endogenous	 and	 exogenous	 L-histidine	 and	
Peptides/mimetics	in	brain	[49].	
2.3	Histamine	in	the	central	nervous	system	(CNS)	
Histamine	 is	 an	 organic	 nitrogenous	 compound,	 formed	 from	 the	
decarboxylation	of	histidine	by	the	enzyme	L-histidine	decarboxylase	(HDC).	It	is	a	
hydrophilic	 vasoactive	 amine.	 Histamine	 is	 generated	 by	 various	 cells	 throughout	
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the	body,	including	CNS	neurons,	gastric	mucosa	parietal	cells,	mast	cells,	basophils	
and	 lymphocytes	 [103].	After	 formation,	 histamine	 is	preferentially	 inactivated	by	
histamine-N-methyltransferase	 in	 brain,	 but	 it	 can	 also	 be	 inactivated	 by	 diamine	





[82].	However,	 this	may	 not	 be	 the	 case	 for	 some	diseases.	 Significant	 changes	 in	
brain	histamine	levels	have	been	observed	in	several	neurological	diseases,	such	as	
multiple	 sclerosis,	 Alzheimer’s	 disease,	 Down’s	 syndrome	 and	 Wernicke’s	
encephalopathy	 [105].	 The	 activity	 of	HDC	 and	 L-histidine	 transporters	may	 both	
contribute	to	the	pathological	processes.		
2.3.1	Histamine	in	nonneuronal	tissues	
Histamine	plays	a	 central	 role	 in	 local	 immune	responses,	 including	allergy	
and	 inflammation,	 immunomodulation	 and	 autoimmunity	 [105].	 It	 can	 cause	
dilation	and	permeability	enhancement	of	substances	across	the	blood	vessels,	and	
regulate	 the	 functions	 of	 monocytes,	 dendritic	 cells,	 T	 cells	 and	 B	 cells	 [103].	 In	





secretion	 as	 a	 local	 stimulator	 [107].	 The	 discovery	 of	 histamine	 receptors	
revolutionized	the	treatment	of	stomach	ulcers	[108].	
2.3.2	Mast	cells		
Histamine	hardly	passes	 through	 the	barrier	 systems	of	 the	brain	 [109].	 In	
the	CNS,	 histamine	 is	 synthesized	by	mast	 cells	 and	histaminergic	neurons,	 under	
the	availability	of	L-histidine	[110-112].	
Mast	 cells	 reside	mainly	on	 the	brain	 side	of	 the	blood-brain	barrier	 (BBB)	
[113],	 concentrated	 along	 the	 blood	 vessels	 in	 thalamus	 [114],	 hippocampus	 and	
entorhinal	 cortex	 [115].	 The	 study	 by	 Goldschmidt	 [116]	 showed	 that	 mast	 cells	
contributed	up	to	90%	of	the	histamine	in	thalamus,	and	up	to	50%	of	whole	brain	
histamine	 levels	 in	 mice.	 Mast	 cell-deficient	 rat	 also	 showed	 reduced	 histamine	





mast	 cells	were	 the	 origin	 of	 histamine	production	only	 during	 the	 first	 postnatal	
days	(until	postnatal	day	4),	responsible	for	the	transient	peak	of	histamine	level	in	
the	 developing	 rat	 brain	 [119,	 120].	 Later	 in	 adulthood,	 the	 histamine-storing	
mature	mast	cells	no	longer	expressed	clearly	detectable	HDC,	which	might	only	act	
as	a	reservoir	for	brain	histamine	[119].	The	number	of	mast	cells	in	adult	rodents	
fluctuates	 greatly	 in	 response	 to	 altered	 physiological	 conditions	 [121],	 varies	
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7).	 The	 histaminergic	 system	was	 first	 characterized	 in	 rat	 brain.	 TMN	 is	 divided	
into	different	subdivisions	according	to	the	accumulation	of	histaminergic	neurons.	
TMN	includes	the	ventral	part	(TMV)	at	the	rostral	and	caudal	sides	of	mammillary	





were	 found	 to	 form	 a	 relatively	 loose	 network	 of	 fine	 varicose	 axons	 [111,	 122],	
reaching	 the	 whole	 CNS	 through	 two	 ascending	 and	 one	 descending	 bundles.	
(Figure	 6)	 One	 of	 the	 ascending	 bundles	 reaches	 the	 hypothalamus,	 the	 diagonal	







The	 histaminergic	 system	 in	 brain	 changes	 during	 development.	 In	




51,	 54].	 The	 transient	 neuronal	 system	undergoes	 some	 transformation,	 and	 then	
stops	 synthesizing	 histamine.	 The	 expression	 of	 histamine	 receptors	 is	 also	 age-




them	 being	 G	 protein	 coupled	 receptors	 (GPCRs).	 H1R-H3R	 are	 abundantly	
expressed	in	the	brain.	H4R	mainly	exists	in	peripheral	tissues	(blood,	spleen,	lung,	
liver,	 and	 gut)	 [119,	 126].	 Using	 isotope	 binding,	 H1R	 was	 densely	 located	 in	
hypothalamus,	aminergic	and	cholinergic	brainstem	nuclei,	thalamus,	hippocampus	





and	 brain	 stem	 in	 the	 human	 brain	 [105,	 127].	 Unlike	 H1R	 and	 H2R,	 H3R	 has	
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constitutive	 activity	 in	vivo.	 H3R	 can	 feedback	 inhibit	 the	 release	 of	 histamine,	 as	
well	 as	 control	 some	 other	 neurotransmitters	 (biogenic	 amines,	 acetylcholine,	
glutamate,	GABA	and	peptidergic	systems)	[105,	128].	
2.3.5	Function	of	histamine	
Histamine	 plays	 a	 very	 important	 role	 in	 the	 CNS,	 regulating	 many	




although	 the	 mechanism	 is	 not	 clearly	 understood.	 Changes	 in	 histamine	 blood	
concentrations	may	cause	disorders	 in	many	physiological	activities	such	as	sleep,	
eating,	 or	 mood	 disorders.	 In	 Alzheimer’s	 disease	 (AD)	 patients,	 blood	 histamine	
levels	can	be	indicator	of	disease	severity,	which	may	be	caused	by	up-regulation	of	
the	histaminergic	system	as	the	global	deterioration	scale	(GDS)	stage	gets	higher.	
















predicted to contain 12 transmembrane domains (TMD),
with the N- and C-termini facing the cytosol. There are
protein stretches with conserved residues found in all
POT family members [56]. One is located in the predicted
end region of the second transmembrane domain, the
following intracellular loop and reaching into TMD3. The
second more conserved signature motif of the PTR-family
is found in the central part of TMD5 and comprises a
stretch of 11 amino acid residues (marked in the topology
model of PEPT1 provided in Fig. 1). In the mammalian
species and some PEPT-related proteins a third conserved
consensus sequence was proposed [21]. So far only a few
POT family members from the large variety of species
expressing the proteins have been characterized function-
ally. The POT family also contains transporters (only in
bacteria, yeast and plants) with the capability of trans-
porting peptides containing more than three amino acid
residues, whereas the mammalian proteins of the PEPT-
and PHT-branches can only transport di- and tripeptides.
The peptide/histidine transporters appear to be phyloge-
netically similar to POT proteins such as CHL1 and
NTR1 found in plants (i.e. Arabidopsis thaliana), which
have been shown to mediate the transport of histidine,
nitrates, di- and tripeptides.
Peptides derived from protein breakdown are variable
in molecular size, net charge and solubility, depending on
the amino acids contained. The PEPT1 and PEPT2
proteins possess the capability for sequence-independent
transport of all 400 different dipeptides and 8000 different
tripeptides derived from the 20 proteinogenic l-a-amino
acids. Whether the PHT1 and PHT2 proteins can transport
the same spectrum of di- and tripeptides is not known, but
in contrast to PEPT1 and PEPT2 they do accept free
histidine as a substrate.
The most simple substrate structures transported by
PEPT1 and PEPT2 are omega-amino fatty acids carrying
a positively and a negatively charged head group
separated by at least four methylene groups [16]. This
Fig. 1 Membrane topology model of PEPT1. Protein domains and
individual amino acid residues that have been identified as relevant
in determining the functional characteristics of the protein are
marked in colours. Predicted protein kinase recognition domains
and glycosylation sites have not been included, since their
relevance has not been proven experimentally
Table 1
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important information concerning the spatial arrangement of
residues involved in peptide and drug transport as catalysed
by mammalian peptide transporters. In addition, it represents
a ligand-bound occluded conformation for an MFS symporter,




PepTSo contains 14 TM helices (Figure 1A), of which helices
H1–H12 adopt the overall fold observed previously for the
MFS transporters LacY, GlpT and EmrD (Figure 1B)
(Abramson et al, 2003; Huang et al, 2003; Yin et al, 2006).
The arrangement of the helices is also consistent with the EM
projection structure of a previously studied POT protein,
DtpD from Escherichia coli (Casagrande et al, 2009). Like
previous MFS transporter structures, the N- and C-terminal
six-helix bundles, formed by helices H1–H6 and H7–H12,
come together to form a ‘V’-shaped transporter, related by a
pseudo two-fold symmetry axis running perpendicular to the
membrane plane. PepTSo has two additional TM helices, HA
and HB, which are inserted into the cytoplasmic loop con-
necting the N- and C-terminal bundles. These form a hairpin-
like structure in the membrane that packs against the per-
iphery of the protein (Figure 1C). Their role is currently
unclear. The apparent absence of these helices in the fungal,
plant and metazoan protein sequences, however, suggests
they do not contribute to any conserved transport mechanism.
The position of PepTSo within the membrane has been
examined using coarse-grained lipid bilayer self-assembly
simulations (Scott et al, 2008). These demonstrate that
PepTSo, including the hairpin helices HA and HB, reproducibly
inserts into a modelled bilayer (Supplementary Figure S2).
The apparent KM for transport of the hydrolysis resis-
tant di-peptide glycylsarcosine is 1.5±0.15 mM, similar
to the value reported for human PepT1 of 1.1±0.1 mM
(Brandsch et al, 1994) (Figure 2A). Uptake of a fluorescent
di-peptide, b-Ala-Lys-Ne-7-amino-4-methylcoumarin-3-acetic
acid (b-Ala-Lys-(AMCA)) in cells overexpressing the PepTSo
gene was reduced upon addition of either di- or tri-alanine
peptides to the media (Supplementary Figure S3). Addition of
L-alanine or the larger tetra-alanine peptide, however, had little
effect, suggesting a similar preference for di- and tri-peptides
as reported for the mammalian transporters (Fei et al, 1994).
Uptake was also abolished by the proton ionophore carbonyl
cyanide p-chlorophenylhydrazone, consistent with a depen-
dence on the proton electrochemical gradient (DmHþ ) to
drive transport. The crystal structure was solved by multiple
isomorphous replacement with anomalous scattering using
mercury derivative crystals and seleno-L-methionine incorpo-
rated protein (Table I and Supplementary Tables I and II).
Assignment of the amino-acid sequence to the density
map was aided through identification of the 22 selenium
and three mercury sites present in the molecule (Supplementary
Figure S4). The model was built and refined using data with
Figure 1 Structure of PepTSo. (A) PepTSo topology. The central and extracellular cavities are shown as a closed diamond and open triangle,
respectively. A bound ligand in the central cavity is represented as a black horizontal bar. Functionally important residues conserved between
PepTSo and metazoan peptide transporters are highlighted by shapes in Supplementary Figure S1 and mapped onto the topology diagram.
(B) PepTSo structure viewed in the plane of the membrane. The two hydrophilic cavities present in the structure are outlined in dashed lines.
The hydrophobic core of the membrane (pale yellow) is distinguished from the interfacial region (light grey). N and C represent the N- and
C-termini, respectively. Bound ligand is shown in black. Helices are labelled. (C) View from the extracellular side of the membrane.
Crystal structure of a POT family oligopeptide transporter
S Newstead et al




	 	intracellular pH recordings and giant patch clamp (GPC) experiments to demonstrate the electrogenic bidirectional character
of dipeptide transport by rabbit PepT1 expressed in Xenopus laevis oocytes. Interestingly, it was also shown that anionic
dipeptides such as Gly–Asp and Asp–Gly were transported in their neutral and negatively charged forms, with high and
low affinities, respectively. On the other hand, cationic dipeptides seemed to be transported in neutral and positively charged
forms, resulting in an excess of transport current as compared with neutral substrates. These results also confirmed the 2:1
proton to anionic dipeptide (Gly–Asp) stoichiometry. A study of hPepT1 expressed in CHO cells showed that valacyclovir
(prodrug of the anthiherpetic agent acyclovir) in conditions of lower pH exists as a cationic species and has lower uptake,
whereas, at higher pH, it exists predominantly as neutral species exhibiting higher uptake values (Balimane and Sinko,
2000). According to the literature, charged substrates were reported to have different binding affinities under various pH
conditions depending on their ionization state. The exact characterization of the pH-dependent substrate transport mecha-
nism by PepT1 still needs further investigation to be more completely understood. Unlike PepT1, PepT2 has been little stud-
ied and appears to have distinct electrogenic transport properties. Indeed, it has been reported that rat PepT2 expression in
Xenopus oocytes reflected an H+: substrate stoichiometry of 2:1 and 3:1 for neutral and anionic dipeptides, respectively (Chen
et al., 1999).
Since the mid-1990s, many approaches were investigated to define the membrane topology of the human PepT and its
functional domains. Several hydropathy plots were predicted using different calculation methods and all of them describe
a protein composed of 12 transmembrane helices (TMH or H) with segments 9 and 10 being connected by a long extracel-
lular loop. This consensus model was partly confirmed by ‘‘epitope-tagging,’’ which also indicated that the C-terminus was
oriented towards the cytoplasm (Covitz et al., 1998). The amino acid sequences of the loop regions of PepT1 and PepT2 are
less conserved than that of the TMH and PepT1 and PepT2 exhibit different kinetic properties, namely substrate affinity for
the dipeptide GlySar, commonly used for assaying peptidomimetic transport by PepT. Several experiments were performed
with chimeras combining different regions of the human PepT1 and rat PepT2. Variable results were observed from these
Fig. 1. Schematic model of peptide transport in epithelial cells from intestine. Di- and tripeptides are the natural substrates co-transported with protons by
peptide transporter isoform 1 (SLC15A1) across the apical epithelial membrane of enterocytes. The activity of the peptide transporter depends upon the
lectrochemical proton gradient, partly established by the apical Na+, H+-exchanger, which depends upon the activity of the basolateral Na+, K+ ATPase.
Rapidly, di- and tripeptides are hydrolyzed in the cytosol, and free amino acids are released into the blood stream via different types of amino acid
transporters located in the basolateral membrane.
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PHT1	 (SLC15A4)	 is	 responsible	 for	 translocating	 L-histidine	 (L-His),	
di/tripeptides	 and	 peptide-like	 drugs	 across	 biological	 membranes.	 	 Previous	
studies	have	indicated	that	PHT1	is	located	in	brain	parenchyma,	however,	its	role	
and	 significance	 in	 brain	 along	 with	 effect	 on	 the	 biodistribution	 of	 substrates	 is	
unknown.	 	 In	 this	 study,	 adult	 gender-matched	 Pht1-competent	 (wildtype)	 and	
Pht1-deficient	(null)	mice	were	used	to	investigate	the	effect	of	PHT1	on	L-His	brain	
disposition	 via	 in	 vitro	 slice	 and	 in	 vivo	 pharmacokinetic	 approaches.	 	 We	 also	
evaluated	the	serum	clinical	chemistry	and	expression	levels	of	select	transporters	
and	 enzymes	 in	 the	 two	 genotypes.	 	 No	 significant	 differences	 were	 observed	
between	 genotypes	 in	 serum	 chemistry,	 body	 weight,	 viability	 and	 fertility.	 	 PCR	
analyses	 indicated	 that	Pept2	 had	a	 compensatory	up-regulation	 in	Pht1	null	mice	
(about	2-fold)	as	compared	 to	wildtype	animals,	which	was	consistent	 in	different	
brain	regions	and	confirmed	by	immunoblots.	 	The	uptake	of	L-His	was	reduced	in	
brain	 slices	 by	 50%	 during	 PHT1	 ablation.	 	 The	 L-amino	 acid	 transporters	
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accounted	 for	 30%	 of	 the	 uptake,	 and	 passive	 (other)	 pathways	 for	 20%	 of	 the	
uptake.	 	 During	 the	 in	 vivo	 pharmacokinetic	 studies,	 plasma	 concentration-time	
profiles	 of	 L-His	 were	 comparable	 between	 the	 two	 genotypes	 after	 intravenous	
administration.	 	 Still,	 biodistribution	 studies	 revealed	 that,	 when	 sampled	 5	 min	
after	 dosing,	 L-His	 values	 were	 28-48%	 lower	 in	 Pht1	 null	 mice,	 as	 compared	 to	
wildtype	animals,	in	brain	parenchyma	but	not	cerebrospinal	fluid.	 	These	findings	
suggest	 that	PHT1	may	play	an	 important	 role	 in	histidine	 transport	 in	brain,	and	
resultant	effects	on	histidine/histamine	homeostasis	and	neuropeptide	regulation.		
3.2	Introduction	
	 PHT1	 (SLC15A4),	 a	 member	 of	 the	 proton-coupled	 oligopeptide	 transporter	
(POT)	 superfamily,	 is	 responsible	 for	 translocating	 various	 di/tripeptides	 and	
peptide-like	 drugs	 across	 biological	 membranes,	 as	 well	 as	 the	 amino	 acid	 L-
histidine	[1].	 	Unlike	two	other	peptide	transporters,	PEPT1	(SLC15A1)	and	PEPT2	
(SLC15A2),	 which	 have	 been	 well	 studied,	 there	 is	 little	 known	 about	 PHT1	
expression,	 localization,	 function	 and	 pharmacological	 relevance.	 PHT1	 is	
abundantly	found	in	the	brain	and	eye	[2,	3].		PHT1	has	an	age-dependent	increase	
in	brain	expression	[4],	similar	to	the	changes	found	in	the	histaminergic	system	[4-
8].	 	 In	 contrast,	PEPT2	shows	an	age-dependent	decrease	 in	brain	expression	and	
PHT1	 function	 dominated	 in	 the	 uptake	 of	 a	 dipeptide	 in	 brain	 slices	 from	 adult	
rodents,	suggesting	a	significant	role	in	regulating	both	endogenous	and	exogenous	
L-histidine	 (L-His)	 and	peptides/mimetics	 in	 brain	 [9].	 	 PHT1	 transcripts	 are	 also	
detected	in	rat	thyroid	gland	[10]	and	skeletal	muscle	[11].		A	recent	study	showed	
that	 PHT1	 and	 PHT2	 are	 involved	 in	 the	 immune	 response	 [12].	 	 These	 authors	
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biological	 functions,	 including	 formation	 of	 the	 myelin	 sheath,	 detoxification	 of	
heavy	 metals,	 and	 the	 manufacturing	 of	 white	 and	 red	 blood	 cells.	 	 It	 is	 also	 a	
precursor	of	histamine,	carnosine,	ergothioneine,	and	vitamin	C	[13].		Studies	on	the	
transport	 of	 L-His	 in	 brain	 would	 extend	 our	 understanding	 of	 neuropeptide	
regulation,	 histamine	 homeostasis,	 and	 potential	 targets	 for	 drug	 delivery	 to	
neuronal	 and	 non-neuronal	 cells.	 	 In	 the	 central	 nervous	 system	 (CNS),	 major	
transporters	for	L-His	include	the	Na+-coupled	neutral	amino	acid	transporters	(e.g.,	
SNATs,	 which	 belong	 to	 the	 SLC38	 family)	 [14,	 15],	 Na+-independent	 amino	 acid	
transporters	(e.g.,	LATs	and	CATs,	which	belong	to	the	SLC7	family)	[16,	17],	some	
members	 of	 the	 Na+-and	 Cl--dependent	 neurotransmitter	 transporter	 family	 (e.g.,	
B0AT2	 and	 NTT4,	 which	 belong	 to	 the	 SLC6	 family)	 [18-20],	 as	 well	 as	 the	
peptide/histidine	 transporters	 (e.g.,	 PHT1	 and	 PHT2,	 which	 belong	 to	 the	 SLC15	
family)	[9,	21].	
	 Histamine,	 one	 of	 the	most	 important	metabolites	 of	 L-His,	 is	 formed	 in	 the	






is	 positively	 correlated	 with	 brain	 histamine	 production	 and,	 consequently	 the	
regulatory	 functions	of	histamine	 [23,	24].	 	 Significant	 changes	 in	brain	histamine	
levels	 have	 been	 observed	 in	 several	 neurological	 diseases,	 such	 as	 multiple	
sclerosis,	 Alzheimer’s	 disease,	 Down’s	 syndrome	 and	 Wernicke’s	 encephalopathy	
[25].	 	 Dysfunction	 of	 HDC	 and	 the	 L-His	 transporters	 in	 brain	 may	 be	 related	 to	
these	neurological	disorders.		
	 In	the	present	study,	we	hypothesized	that	PHT1	ablation	would	substantially	
reduce	 the	uptake	of	 L-His	 in	 the	brain	of	 adult	mice.	 	 Initial	 phenotypic	 analyses	
were	performed	in	Pht1-competent	(wildtype)	and	Pht1-deficient	(null)	mice,	along	
with	 gene	 expression	 levels	 of	 POTs	 and	 select	 transporter/enzyme	 proteins.		
Subsequent	studies	evaluated	the	functional	activity	of	PHT1	by	studying	the	in	vitro	




	 L-[3H]histidine	 (500	 mCi/mmol),	 L-[14C]histidine	 (322	 mCi/mmol),	
[14C]mannitol	 (53	 mCi/mmol)	 and	 [3H]dextran-70,000	 (110	 mCi/mg)	 were	
purchased	 from	 American	 Radiolabeled	 Chemicals	 (St.	 Louis,	 MO).	 Unlabeled	 L-
histidine,	 mannitol	 and	 dextran-70,000	 were	 purchased	 from	 Sigma-Aldrich	 (St.	






	 Gender-	 and	 age-matched	 Pht1-competent	 (wildtype	 or	 Pht1+/+)	 and	 Pht1-
deficient	 (null	or	Pht1-/-)	mice,	7-10	weeks	old,	were	used	 in	 this	study	 [26].	 	PCR	
analysis,	using	genomic	DNA	isolated	from	tail	biopsies,	was	performed	to	confirm	
the	subsequent	production	of	Pht1	null	mice.		The	Pht1	gene	had	a	forward	primer	
5´-GATCGAGGTCCAGAAGCCACTCG-3´	 and	 a	 reverse	 primer	 5´-
GAGTTGTGTCACTCACCCACTTCT-3´.	 	 The	 Neo	 gene,	 inserted	 during	 homologous	
recombination	 in	 Pht1	 null	 mice,	 had	 a	 forward	 primer	 5´-
GGAGAGGCTATTCGGCTATG-3´	and	a	reverse	primer	5´-GCTCTTCAGCAATATCACGG-
3´.	 	 All	 animals	 were	 bred	 on	 a	 C57BL/6	 background	 (≥	 99%).	 	 The	 mice	 were	
housed	 in	 a	 temperature-controlled	 environment	with	 12	 h	 light	 and	 dark	 cycles,	
and	 received	 a	 standard	 diet	 and	 water	 ad	 libitum	 (Unit	 of	 Laboratory	 Animal	










	 Quantitation	 of	 POTs	 (Pept1,	 Pept2,	 Pht1	 and	 Pht2),	 select	 amino	 acid	
transporters	 (Lat1,	Snat1,	Snat3	 and	Ntt4)	 and	 histidine	 decarboxylase	 (Hdc)	was	
performed	in	several	tissues	of	adult	wildtype	and	Pht1	null	mice	using	a	7300	Real-
Time	 PCR	 system	 (Applied	 Biosystems,	 Foster	 City,	 CA)	 [28].	 	 Tissues	 of	 interest	
included	 cerebral	 cortex,	 cerebellum,	 hippocampus,	 hypothalamus	 and	 choroid	
plexus.		In	brief,	2.0	μg	of	total	RNA,	isolated	using	the	RNeasy	Plus	Mini	Kit	(Qiagen,	
Valencia,	 CA),	 was	 reverse-transcribed	 into	 cDNA	 using	 the	 Omniscript	 RT	 Kit	
(Qiagen,	Valencia,	CA)	with	16-mer	 random	primers.	 	The	mouse	Gapdh	 gene	was	





relative	 levels	of	 target	gene	 transcripts	 in	mice,	where	 the	ratio	of	 target	gene	 to	
Gapdh	was	equal	to	2−ΔCT,	ΔCT	=	CT(gene)	−	CT(Gapdh).	
	 Immunoblot	 analysis	 was	 performed	 for	 PEPT2	 protein,	 as	 described	
previously	 with	 minor	 changes	 [29].	 	 Tissue	 lysis	 buffer	 consisted	 of	 neuronal	
protein	 extraction	 reagent	 (Thermo	 Scientific,	 Rockford,	 IL)	 with	 the	 addition	 of	
proteinase	 inhibitor	 cocktail.	 Kidney	 protein	 served	 as	 positive	 control	 for	 PEPT2	
[30].	
3.3.5	In	vitro	uptake	of	L-His	in	regional	brain	slices	








times	were	 1,	 3,	 5	 and	 10	min,	 after	which	 time	 1.5	mL	 ice-cold	 aCSF	 buffer	was	
added	 to	 the	 chamber	 to	 terminate	 the	 reaction.	 	 The	 samples	were	 immediately	
filtered	 through	100	μm	nylon	mesh	and	 then	washed	 five	 times	with	1.5	mL	 ice-
cold	aCSF	buffer.		The	filter	(and	tissue	slices)	were	transferred	to	a	scintillation	vial	
containing	 0.33	mL	 hyamine	 hydroxide	 and	 left	 overnight	 at	 37°C	 to	 dissolve	 the	
tissue.	 	 The	 samples	were	 then	mixed	with	 a	 7.0-mL	 aliquot	 of	 Cytoscint	 cocktail	
(MP	Biomedicals,	Solon,	OH).		Radioactivity	was	measured	using	a	Beckman	LS	6000	
SC	dual-channel	liquid	scintillation	counter	(Beckman	Coulter	Inc.,	Fullerton,	CA).			












	 To	 further	 investigate	 the	 contribution	 of	 amino	 acid	 transporters	 on	 L-His	
uptake,	as	well	as	the	substrate	specificity	of	PHT1,	excess	amounts	(5	mM)	of	L-His,	
L-glutamine,	L-leucine,	L-asparagine	or	BCH	(2-amino-2-norbornanecarboxylic	acid)	










in	 0.2-mL	 microcentrifuge	 tubes	 containing	 heparin.	 	 Heparinized	 blood	 samples	
were	centrifuged	immediately	at	3000	g	for	3	min	at	ambient	temperature.		A	5-	to	
10-μl	 aliquot	 of	 plasma	 was	 then	 mixed	 with	 6.0	 mL	 of	 Cytoscint	 cocktail.		
Radioactivity	was	measured	using	a	dual-channel	liquid	scintillation	counter.			
	 A	 single	 CSF	 sample	 (5	 μL)	 was	 obtained	 from	 the	 cisterna	 magna	 of	 each	
mouse	 at	 2,	 5,	 10,	 20	 and	 30	 min	 after	 dosing.	 	 The	 mouse	 was	 euthanized	 and	
decapitated,	 and	 select	 tissues	 of	 brain	 (e.g.	 cerebral	 cortex,	 cerebellum,	
hypothalamus	and	hippocampus)	were	then	isolated,	blotted	dry	and	weighed.		The	
samples	 were	 dissolved	 in	 330	 μL	 of	 1	 M	 hyamine	 hydroxide	 and	 incubated	





plasma	 concentrations	 of	 L-His	 after	 intravenous	 bolus	 dosing	 using	
Phoenix/WinNonlin	 version	 6.4	 (Pharsight	 Inc.	 Mountain	 View,	 CA).	 	 Total	 area	





	 All	 the	 experimental	 results	 were	 reported	 as	 mean	 ±	 SE.	 	 A	 two-tailed	
unpaired	 Student’s	 t-test	 was	 applied	 when	 comparing	 statistical	 differences	
between	 two	 treatment	 groups.	 	 For	 multiple	 comparisons,	 one-way	 analysis	 of	






	 These	studies	were	performed	 to	 test	 for	obvious	differences	 in	 fundamental	
characteristics	between	the	two	mouse	genotypes.	 	 In	 this	regard,	PCR	analyses	of	
genomic	 DNA	 extracted	 from	 tail	 biopsies	 demonstrated	 that	 Pht1	 genomic	 DNA	










other	 relevant	 transporters	 and	 enzymes.	 	 Protein	 expression	 for	 a	 particular	
transporter	 was	 also	 performed	 in	 select	 cases.	 	 PCR	 analyses	 in	 wildtype	 mice	
indicated	 that	 Pht1	 was	 expressed,	 along	 with	 Pept2,	 in	 the	 cerebral	 cortex,	
cerebellum,	hypothalamus,	hippocampus	and	choroid	plexus	(Fig.	2).		Interestingly,	
Pept2	showed	a	compensatory	up-regulation	in	Pht1	null	mice	(about	2-fold),	which	
was	 consistently	 observed	 in	 the	 different	 brain	 regions.	 	 Expression	 of	 other	
peptide	transporters	(Pept1	and	Pht2)	and	Hdc	were	comparable	between	the	two	
genotypes.	 	Some	of	 the	amino	acid	 transporters	had	different	 transcription	 levels	
between	genotypes,	however,	there	was	no	consistent	pattern	in	the	different	brain	
regions.	 	 The	 upregulation	 of	 Pept2	 in	 Pht1	 null	 mouse	 brain	 was	 confirmed	 by	
immunoblot	 analysis	 (Fig.	 3).	 	 PEPT2	protein	 could	 be	 detected	 in	 different	 brain	






uptake	of	a	model	 substrate,	L-His,	using	an	 in	vitro	model.	 	L-[3H]His	uptake	was	
linearly	 correlated	with	 time	over	 the	 first	3-10	min,	with	no	 consistent	 trend	 for	
either	 genotype	or	 regional	brain	 slice	 (Fig.	 4A).	 	As	 a	 result,	 3-min	uptakes	were	
used	 to	 estimate	 the	 initial	 rates	of	 L-His,	which	were	 reduced	by	37-60%	during	
PHT1	ablation	depending	upon	the	regional	brain	slice	studied	(Fig.	4B).		To	assess	
the	 substrate	 specificity	 of	 PHT1,	 the	 3-min	 uptake	 of	 L-[3H]His	was	 evaluated	 in	
hypothalamus	by	 inhibition	studies	(Fig.	5).	 	 In	wildtype	mice,	 the	uptake	of	L-His	
was	reduced	to	20%	of	normal	by	the	amino	acids	L-histidine,	L-glutamine,	L-lysine	
and	L-asparagine,	 and	 to	45-72%	of	normal	by	 the	dipeptides	glycylsarcosine	and	
carnosine	(5	mM	each).		In	contrast,	residual	uptake	values	of	L-His	in	Pht1	null	mice	
were	 similar	 between	 control	 animals	 (L-His	 alone)	 and	 in	 the	 presence	 of	
dipeptides.	 	 In	 the	 presence	 of	 amino	 acids,	 values	 for	 L-His	 uptake	 were	













in	 Pht1	 null	 mice,	 as	 compared	 to	 wildtype	 animals,	 in	 the	 cerebral	 cortex,	
cerebellum,	 hippocampus	 and	 hypothalamus,	 but	 not	 CSF,	 when	 sampled	 5	 min	
after	dosing	(Fig.	7).			
3.5	Discussion	
	 Compared	 with	 PEPT1	 and	 PEPT2,	 little	 is	 known	 about	 the	 expression,	
localization,	 function	 and	 pharmacological	 relevance	 of	 PHT1,	 another	member	 of	
the	 SLC15	 family.	 	 Based	 on	 limited	 previous	 reports	 [2,	 9],	 PHT1	 protein	 was	
expressed	in	the	brain	and	retina	of	rat,	and	showed	high	affinity	for	L-His	in	Pht1-
transfected	 Xenopus	 laevis	 oocytes	 [2].	 	 PHT1	 protein	 was	 also	 expressed	 in	 the	
brain	 of	 adult	 but	 not	 neonatal	 rats	 and	 mice,	 showing	 a	 dominant	 role	 in	
glycylsarcosine	brain	uptake	in	adult	rodents	[9].		However,	the	significance	of	PHT1	
in	 uptake	 of	 its	 amino	 acid	 substrate,	 L-His,	 in	 brain	 was	 not	 evaluated	 in	 these	
studies	 [4].	 	 Thus,	 the	 in	 vitro	 brain	 slice	 and	 in	 vivo	 pharmacokinetic/	
biodistribution	 studies	 proposed	here	 for	 L-His	 in	 brain	 are	 a	 good	 starting	 point	
from	 which	 to	 understand	 the	 role	 and	 significance	 of	 PHT1	 in	 neuropeptide	
regulation,	 histamine	homeostasis,	 and	 the	potential	 for	 targeted	drug	delivery	 to	
neuronal	and	non-neuronal	cell	types.			
	 Several	 novel	 findings	 were	 revealed	 through	 phenotypic	 analyses,	 in	 vitro	
brain	 slice	uptake	 incubation	and	 in	vivo	 pharmacokinetic	 studies	 in	wildtype	and	
Pht1	null	mice.	Specifically:	1)	Pht1	null	mice	displayed	no	obvious	phenotype	and	
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had	 serum	 clinical	 chemistry	 values	 that	 were	 comparable	 to	 wildtype	 mice;	 2)	
PHT1	 was	 expressed,	 along	 with	 PEPT2,	 in	 the	 brain	 parenchyma	 (cortex,	
cerebellum,	 hippocampus	 and	hypothalamus)	 of	wildtype	mice;	 3)	 the	mRNA	 and	
protein	 levels	 of	 PEPT2	were	 significantly	 up-regulated	 in	Pht1	 null	mouse	 brain,	
suggesting	a	compensatory	role	of	PEPT2	in	these	mice;	4)	the	uptake	of	L-[3H]His	
was	 about	 50%	 lower	 in	Pht1	 null	mouse	brain	 slices	 as	 compared	 to	 those	 from	
wildtype	mice,	indicating	that	PHT1	makes	a	significant	contribution	towards	L-His	
uptake	 into	 brain	 parenchyma;	 5)	 the	 uptake	 of	 L-[3H]His	 could	 be	 inhibited	 by	
dipeptides	 and,	 in	 addition	 to	 L-His,	 by	 several	 other	 amino	 acids;	 and	 6)	 PHT1	
deficiency	did	not	affect	the	in	vivo	systemic	exposure	of	L-[14C]His	in	plasma	or	CSF,	




the	 inhibition	profiles	of	wildtype	and	Pht1	 null	mice.	 	For	example,	 in	 comparing	
the	 inhibition	studies	 in	wildtype	mice	alone,	 the	amino	acids	 (except	 for	 leucine)	
reduced	 the	 uptake	 of	 L-His	 to	 about	 20%	 of	 control,	 whereas	 the	 dipeptides	
reduced	 L-His	 uptake	 to	 40-65%	 of	 control	 (all	 changes	were	 significant).	 	 These	
profiles	reflected	the	collective	contributions	of	PHT1,	amino	acid	transporters	and	
nonsaturable/passive	 pathways	 for	 the	 uptake	 of	 L-His	 in	 wildtype	 mice.	 	 In	




Pht1	 null	 mice	 was	 only	 50%	 of	 the	 control	 value	 in	 wildtype	 mice,	 indicating	 a	
major	 influence	 of	 PHT1	 in	 the	 uptake	 of	 L-His.	 Thus,	 these	 profiles	 reflected	 the	
collective	 contributions	 of	 amino	 acid	 transporters	 and	 nonsaturable/passive	
pathways	 for	 the	 uptake	 of	 L-His	 in	 the	 absence	 of	 PHT1.	 	 Overall,	 the	 combined	
mechanisms	 for	 L-His	 uptake	 in	 brain	 (hypothalamus)	 were	 PHT1	 (50%),	 amino	
acid	transporters	(30%)	and	nonsaturable/passive	processes	(20%).		





slices	 [4].	 	 Another	 POT,	 PHT2	 can	 also	 recognize	 L-His	 as	 a	 substrate,	 but	 this	
transporter	 is	barely	detected	 in	brain	 [3,	9],	as	 is	PEPT1	 [30].	 	The	effect	of	Pht1	




may	 suggest	 a	 compensatory	 role	 of	 PEPT2	 as	 a	 transporter	 for	 di/tripeptides	 in	
brain	(Fig.	3).	 	This	was	not	observed	 in	other	 tissues,	such	as	kidney,	 testis,	 lung,	
intestine,	 spleen	 or	 colon	 (data	 not	 shown).	 	 As	 expected,	 there	 was	 no	 gene	
expression	 of	Pept1	 or	Pht2	 in	 the	 brain	 of	 both	 genotypes,	which	was	 consistent	





PHT1	 expression	 will	 not	 be	 synaptic,	 its	 expression	 may	 reflect	 a	 cell	 body	 or	
axonal	distribution	in	neurons.			
	 Although	brain	barrier	systems	determine	the	concentration	of	amino	acids	in	
CSF	 and	 extracellular	 fluid	 (ECF),	 transporters	 expressed	 on	 the	 membranes	 of	
brain	 parenchyma	 cells	 also	 participate	 in	 the	 regulation	 of	 intracellular	 fluid	
homeostasis	 [33].	 	 More	 importantly,	 transporters	 in	 brain	 parenchyma	 are	
responsible	 for	 the	 translocation	 of	 metabolic	 substrates,	 neurotransmitters	 and	
neurotransmitter	 precursors,	which	 can	 regulate	 signaling	 pathways	 [34].	 	 Amino	
acid	 transporters	of	L-His	 in	brain	parenchyma	 include	the	Na+-dependent	neutral	
amino	 acid	 transporters	 (SNATs,	 SLC38	 family)	 [14,	 15],	 some	 members	 of	 the	
sodium-	and	chloride-dependent	neurotransmitter	transporter	family	(SLC6	family)	
(e.g.	B0AT2,	and	NTT4)	[18-20],	Na+-independent	amino	acid	transporters	(e.g.	LATs	





glutamine	 in	 the	 glutamate/glutamine	 cycle	 [36].	 	 Affinity	 of	 SNATs	 to	 L-His	 is	
relatively	 low,	with	Michaelis-Menten	 (Km)	values	 in	 the	millimolar	 range	 [37-39].	




	 Another	 important	 consideration	 was	 that	 of	 differences	 in	 the	 gene	
expression	of	amino	acid	transporters	in	wildtype	and	Pht1	null	mice.		In	this	regard,	
there	appeared	to	be	no	consistent	pattern	of	change	in	either	a	specific	amino	acid	
transporter	 or	 brain	 region	 with	 respect	 to	 the	 up-/down-regulation	 between	
genotypes.		Using	hypothalamus	as	an	example,	since	the	in	vitro	inhibition	studies	
were	performed	in	this	brain	region	along	with	in	vivo	studies,	the	only	amino	acid	
transporter	 that	 showed	 a	 statistically	 significant	 difference	 was	 Ntt4,	 with	 gene	
expression	being	reduced	by	only	12%	(Fig.	2).	 	However,	 in	Pht1	null	mice,	the	 in	
vivo	uptake	of	L-His	was	reduced	2-fold	relative	to	the	values	observed	in	wildtype	
animals	 (Fig.	 6).	 	 Moreover,	 similar	 reductions	 in	 the	 in	 vivo	 L-His	 uptake	 were	
observed	in	other	brain	regions	even	though	Ntt4	gene	expression	increased	2-fold	
in	cortex,	had	no	change	in	cerebellum,	and	was	reduced	only	20%	in	hippocampus.		
These	 findings	make	 it	unlikely	 that	changes	 in	 the	gene	expression	of	amino	acid	
transporters	can	explain	 the	differences	 in	 transport	acitivity	of	L-His	during	Pht1	









glycylsarcosine)	and	excess	L-His.	 	However,	 an	 interesting	 finding	was	 that	 some	
amino	acids	(not	including	L-leucine)	and	a	system	L-amino	acid	transport	inhibitor,	
BCH,	substantially	reduced	the	uptake	of	L-His	via	PHT1.		This	phenomenon	has	not	





vivo	 with	 a	 28-48%	 reduction	 into	 uptake	 into	 brain	 regions	 after	 intravenous	
dosing	(Fig.	7).		These	results	suggest	a	role	of	PHT1	at	the	blood-brain	barrier.		Carl	
et	 al.	 [44]	 reported	 the	 protein	 expression	 of	 PHT1	 in	 hCMEC/D3	 cells,	 an	
immortalized	human	brain	endothelial	 cell	 line	 commonly	used	 for	 in	vitro	 blood-
brain	 barrier	 studies.	 	 Those	 cells	 showed	 some	 evidence	 of	 polarized	 L-His	 and	











Increased	 neurotoxicity	 was	 also	 observed	 in	 Pept2(-/-)	 knockout	 mice	 given	
chronic	administration	of	the	heme	precursor	5-aminolevulinic	acid	[47]	as	well	as	
increased	analgesia	in	Pept2(-/-)	knockout	mice	given	the	endogenous	neuropeptide	
L-kyotorphin	 [48].	 	While	 this	 study	 represents	an	analysis	of	L-His	disposition	 in	
the	brain	of	wildtype	and	Pht1	null	mice,	as	evaluated	by	in	vitro	brain	slices	and	in	
vivo	biodistribution	studies,	these	results	allow	us	to	explore	subsequently	if	these	
kinetic	 differences	 will	 translate	 into	 pharmacological	 and/or	 pathological	
differences.		Still,	in	their	initial	study	using	wildtype	and	Pht1	null	mice,	Sasawatari	
et	 al.	 [27]	 reported	 that	 PHT1	 promoted	 a	 dextran	 sodium	 sulfate-induced	 colitis	
through	 its	 interaction	 with	 Toll-like	 receptor	 9	 and	 NOD1-dependent	 innate	
immune	responses.			
	 Taken	as	a	whole,	it	appears	that	PHT1	accounted	for	50%	of	the	total	uptake	
of	 L-His	 in	 brain	 slices	 and	 L-amino	 acid	 transporters	 for	 30%	 of	 the	 uptake.	 	 In	
addition,	PHT1	ablation	significantly	affected	the	in	vivo	blood	to	brain	distribution	
of	L-His.	 	These	 findings	are	the	 first	of	 their	kind	and	suggest	 that	PHT1	plays	an	














































aData	 are	 expressed	 as	 mean	 ±	 SE	 (number	 of	 mice).	 BUN,	 urea	 nitrogen;	 ALT,	
alanine	 aminotransferase;	 ALP,	 alkaline	 phosphates;	 and	 AST,	 aspartate	
aminotransferase.	 No	 statistical	 differences	 were	 observed	 between	 the	 two	
genotypes,	as	determined	by	a	Student’s	t-test.				 	
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Table	 3-3	 Noncompartmental	 pharmacokinetic	 analysis	 of	 [14C]L-histidine	 in	
wildtype	 (WT)	 and	Pht1	 null	 (Null)	mice	 after	 1	 nmol/g	 intravenous	
bolus	dose	
Parameter		 Unit	 WT		 Null		
AUC0-30	 μM*min	 21.7	(4.8)	 24.6	(4.7)	
AUC0-∞		 μM*min	 42.0	(8.0)	 43.4	(6.3)	
CL	 mL/min	 0.71	(0.15)	 0.59	(0.10)	
Vss	 mL	 8.4	(0.7)	 7.5	(0.7)	
t1/2		 min	 13.3	(3.8)	 11.1	(1.6)	
λz		 min-1	 0.084	(0.015)	 0.083	(0.014)	
MRT		 min	 17.9	(4.6)	 15.7	(2.3)	











Pht1	 gene-specific	 primer	 in	 Pht1	 null	 mice;	 Neo	 (+/+),	 neomycin-















Figure	3-3	 Immunoblots	 of	 PEPT2	 protein	 in	 cerebral	 cortex,	 cerebellum,	
hippocampus	 and	hypothalamus	 of	wildtype	 (+/+)	 and	Pht1	 null	 (-/-)	
mice.	 	β-Actin	served	as	a	 loading	control.	 	Kidney	from	wildtype	mice	
was	a	positive	 control	 for	PEPT2	protein.	 	Fold	 change	 represents	 the	








Genotype	 -/-	 +/+	 -/-	 +/+	 -/-	 +/+	 -/-	 +/+	 -/-	 +/+	 +/+	















Figure	3-4	 Uptake	 of	 2	 μM	L-[3H]histidine	 in	 brain	 slices	 of	 adult	wildtype	 (WT)	
and	Pht1	null	(Null)	mice	as	a	function	of	time	(A)	and	under	initial-rate	
conditions	(i.e.,	3-min	incubation)	(B).	Values	are	mean	±	SE	(n	=	4).		*p	






wildtype	 (WT)	 and	 Pht1	 null	 (Null)	 mice	 in	 the	 absence	 (control)	 or	
presence	 of	 potential	 inhibitors	 (5	mM).	 Values	 are	mean	 ±	 SE	 (n=4).		
All	treatment	groups	were	compared,	regardless	of	genotype,	and	those	
treatments	with	 the	 same	capital	 letter	 (i.e.,	A,	B,	C,	D,	or	E)	were	not	











































































































Figure	3-7	 Tissue	and	cerebrospinal	 fluid	 (CSF)	concentrations	of	L-[14C]histidine	
in	 brain	 regions	 of	 wildtype	 (WT)	 and	 Pht1	 null	 (Null)	mice	 after	 1	
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nmol/g	intravenous	bolus	dose.		Data	are	expressed	as	mean	±	SE	(n	=	





































































































































Purpose:	 To	 develop	 a	 semi-mechanistic	 population	 pharmacokinetic	 model	 to	
quantitate	 the	disposition	kinetics	of	 L-histidine,	 a	peptide-histidine	 transporter	1	
substrate,	in	plasma,	cerebrospinal	fluid	and	brain	parenchyma	of	wildtype	and	Pht1	
knockout	mice.			
Methods:	 L-[14C]Hisidine	 (L-His)	 was	 administrated	 to	 wildtype	 (WT)	 and	 Pht1	
knockout	 (KO)	 mice	 via	 tail	 vein	 injection.	 Serial	 samples	 from	 plasma,	
cerebrospinal	fluid	(CSF)	and	brain	parenchyma	were	collected.	A	pharmacokinetic	
(PK)	 model	 was	 developed	 using	 non-linear	 mixed	 effects	 modeling	 (NONMEM).	
The	 disposition	 of	 L-His	 between	 the	 plasma,	 brain,	 and	 CSF	was	 described	 by	 a	
combination	 of	 PHT1-mediated	 uptake,	 passive	 diffusion,	 CSF	 bulk	 flow	 and	 first-
order	microrate	constants.	
Results:	 The	 profiles	 of	 L-His	 in	 plasma,	 CSF	 and	 brain	 parenchyma	 were	 best	
described	 by	 a	 four-compartment	 model.	 A	 more	 rapid	 uptake	 of	 L-His	 in	 brain	




Conclusions:	 A	 semi-mechanistic	 population	 pharmacokinetic	 model	 was	
successfully	 developed,	 for	 the	 first	 time,	 to	 quantitatively	 characterize	 the	
disposition	 kinetics	 of	 L-His	 in	 brain	 under	 in	 vivo	 conditions.	 The	model	 should	
provide	 useful	 in	 predicting	 the	 uptake	 of	 L-His,	 and	 possibly	 other	 PHT1	
peptide/mimetic	substrates,	for	drug	delivery	to	the	brain.	
4.2	Introduction	
Proton-coupled	 oligopeptide	 transporters	 (POTs)	 are	 responsible	 for	
translocating	 various	 di/tripeptides	 and	 peptidomimetics	 across	 biological	
membranes	 [1,	2].	They	have	a	significant	 influence	on	 the	pharmacokinetics	 (PK)	
and	 pharmacodynamics	 (PD)	 of	 their	 substrates	 [3-5].	 To	 date,	 four	 mammalian	
members	 of	 the	 POT	 superfamily	 have	 been	 identified,	 including	 peptide	
transporter	1	(PEPT1)	and	2	(PEPT2),	and	peptide/histidine	transporter	1	(PHT1)	
and	 2	 (PHT2).	 Unlike	 PEPT1	 and	 PEPT2,	 which	 have	 been	 well	 studied	 through	
experiments	and	modeling	approaches	[3-5],	there	is	 limited	information	available	
for	PHT1,	especially	regarding	its	in	vivo	PK	properties.		
PHT1	 was	 first	 been	 cloned	 from	 rat	 brain	 in	 1997	 [6].	 It	 was	 highly	
expressed	in	the	brain	and	retina	of	rat,	and	showed	high	affinity	to	L-histidine	(L-
His)	in	Pht1-transfected	Xenopus	laevis	oocytes	[6,	7].	Our	preliminary	studies	in	rat	
and	 mice	 showed	 that	 PHT1	 had	 a	 dominant	 function	 in	 brain	 uptake	 of	 the	
dipeptide	 substrate	 glycylsarcosine	 [8],	 as	 well	 as	 in	 regulating	 the	 brain	




diseases	 related	 to	 TLR9	 stimulation,	 such	 as	 lupus,	 colitis	 and	 persistent	 viral	
infection	 [12-14].	 Recent	 genome-wide	 association	 studies	 on	 systemic	 lupus	
erythematosus	 identified	PHT1	variants	 as	 an	Asian-specific	 locus	 for	 this	disease	
[15-17].		
L-histidine	 (L-His)	was	chosen	as	 the	model	 substrate	of	PHT1	used	 in	 this	
study.	 It	 is	 one	 of	 the	 essential	 amino	 acids,	 which	 can	 be	 degraded	 to	 many	
important	metabolic	products	[18].	One	of	the	most	important	metabolites	of	L-His	
in	 the	 brain	 is	 histamine,	 a	 neurotransmitter.	 It	 is	 known	 that	 histamine	 has	
difficulty	passing	through	the	barrier	systems	of	the	brain	[19,	20].	The	production	
of	 histamine	 in	 the	 central	 nerves	 system	 (CNS)	 is	 not	 only	 dependent	 upon	 the	
activity	 of	 histidine	 decarboxylase	 (HDC)	 [19],	 but	 also	 on	 the	 availability	 of	 its	
precursor,	L-His.	Therefore,	the	entry	of	L-His	in	brain	is	correlated	with	histamine	
homeostasis	 [21,	 22].	 Brain	 histamine	 is	 produced	 in	 histaminergic	 neuronal	 and	
mast	 cells.	 There	 are	 several	 transporters	 responsible	 for	 translocating	 L-His	 into	
the	 brain	 cells,	 including	 L-amino	 acid	 transporters	 (e.g.,	 SNATs,	 LATs	 and	 CATs)	
and	PHT1	 [8,	 11,	 23-26].	However,	 it	 appears	 that	 PHT1	 accounts	 for	 50%	of	 the	
uptake	 of	 L-His,	 as	 determined	 in	 mouse	 brain	 slices,	 while	 L-amino	 acid	
transporters	account	for	30%	and	other	unidentified	non-saturable	processes	for	20%	
of	the	uptake	[8,	9].		
Previous	 studies	 suggest	 that	 PHT1	 may	 play	 an	 important	 role	 in	
histidine/histamine	 homeostasis	 in	 brain,	 as	 well	 as	 in	 neuropeptide	 regulation.	
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Thus,	 understanding	 the	 uptake	 kinetics	 of	 PHT1	 substrates	 could	 facilitate	 the	
development	of	drug	delivery	strategies	 for	 the	treatment	of	neurological	diseases	
related	to	brain	histamine	levels.	A	semi-mechanistic	model	could	provide	a	useful	
tool	 in	 predicting	 the	 brain	 entry	 of	 PHT1	 substrates.	 In	 order	 to	 construct	 the	
model,	 a	 nonlinear	 mixed	 effects	 modeling	 (NONMEM)	 approach	 was	 performed.	
NONMEM	 is	widely	 used	 in	 analyzing	 population	 PK	 data	 by	 virtue	 of	 addressing	
variability	with	different	sources.	In	this	study,	a	population	PK	model	of	L-His	was	
developed	in	wildtype	and	Pht1-deficient	mice.	By	analyzing	and	comparing	the	data	




Gender-	 and	 age-matched	 Pht1-competent	 (wildtype	 or	 WT)	 and	 Pht1-
deficient	 (knockout	 or	 KO)	 mice	 (8	 to	 10	 weeks)	 were	 used	 in	 this	 study.	 The	
genotype,	gender,	age	and	body	weight	were	recorded	before	the	experiments.	Pht1	
KO	 mice	 were	 a	 generous	 gift	 of	 Dr.	 Noriko	 Toyama-Sorimachi	 [14].	 All	 animals	










laboratory	 [27].	 In	 brief,	 a	 100-μl	 volume	 of	 L-[14C]His	 solution	 (1	 nmol/g,	 0.4	
μCi/mouse)	was	administrated	to	WT	and	Pht1	KO	mice	via	tail	vein	injection.	Serial	
blood	samples	(15-20	μl),	via	tail	nicks,	were	then	collected	at	0.5,	1,	2,	5,	10,	20,	and	




times	 (e.g.,	 2,	 5,	 10,	 20	 or	 30	 min	 after	 dosing).	 The	 samples	 were	 weighed	 and	
dissolved	in	330	μl	of	1	M	hyamine	hydroxide	and	incubated	overnight	at	37°C.	An	
intravenous	 bolus	 injection	 of	 [3H]dextran-MW	 70,000	 (0.25	 μCi/mouse)	 was	
administered	 just	 prior	 to	 harvesting	 the	 tissue	 samples	 to	 correct	 for	 vascular	
space.	
4.3.3	Population	PK	modeling	of	L-His	in	plasma,	CSF	and	brain	parenchyma	
The	 concentration-time	 profiles	 of	 these	 biological	 fluids	 and	 tissue	 were	
analyzed	 using	 non-linear	 mixed	 effects	 modeling	 with	 NONMEM	 v7.3	 (ICON	
Development	 Solutions,	 MD,	 USA).	 A	 subroutine	 ADVAN6	 TRANS1	 and	 the	 first-
order	conditional	estimation	with	interaction	were	used	to	build	the	compartment	
models	throughout	the	modeling	procedure.	Model	development	was	guided	by	the	
likelihood	 ratio	 test	 using	objective	 function	 values,	 graphical	 goodness-of-fit,	 and	
non-parametric	 bootstrap	 analysis.	 A	 stepwise	 compartmental	 model	 building	
approach	 was	 performed	 in	 model	 development	 to	 characterize	 the	 disposition	
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kinetics	of	 L-His	 in	 the	plasma,	CSF	and	brain	parenchyma.	First,	 a	PK	model	was	
developed	 for	 the	 plasma	 concentration-time	 data,	 and	 one-,	 two-,	 and	 three-
compartment	models	were	compared.	Once	the	model	for	the	plasma	concentration-









= −K12 × A1 + K21 × A2 − K13 × A1 + K31 × A3 −
Vmax,PHT1 × A1
Km,PHT1 iV1 + A1
×Genotype








where	 A1,	 A2,	 A3	 and	 A4	 were	 the	 amount	 of	 L-His	 in	 plasma	 central,	 plasma	
peripheral,	 brain	 parenchyma	 and	 CSF	 compartments,	 respectively.	 V1	 was	 the	
volume	of	distribution	of	the	plasma	central	compartment.	K10,	K12,	K21,	K13,	K31,	K14,	
K41,	 Kbulk,	 K34	 and	 K43	 were	 the	 first-order	 microrate	 constants	 between	 the	
respective	 compartments.	 Genotype	 was	 the	 indicator	 for	 the	 mouse	 genotype	
dA2
dt
= K12 × A1 −K21 × A2
dA3
dt
= K13 × A1 −K31 × A3 +
Vmax,PHT1 × A1
Km,PHT1iV1 + A1
×Genotype + K43 × A4 −K34 × A3
dA4
dt
= K14 × A1 −K41 × A4 −Kbulk × A4 −K43 × A4 + K34 × A3
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(Genotype	=	1	for	WT,	Genotype	=	0	for	KO).	In	WT	mice,	L-His	entered	the	brain	via	
active	 transport	 by	 PHT1	 as	 described	 by	 a	Michaelis-Menten	 term	 (Vmax,PHT1	 and	
Km,PHT1),	 and	 by	 other	 pathways	which	were	 simplified	 as	 one	 first-order	 process	
(K13).	There	was	no	PHT1	function	in	the	KO	mice.	There	was	passive	diffusion	of	L-
His	describing	its	exchange	between	the	brain	parenchyma	and	CSF	compartments.	
The	 intercomparment	 clearance	 (Q2),	 which	 was	 assumed	 to	 be	 inversely	




The	 distribution	 of	 L-His	 between	 plasma	 and	 CSF	was	 also	 assumed	 to	 be	 first-
order	 processes.	 In	 addition,	 L-His	 was	 drained	 from	 CSF	 to	 plasma	 central	
compartment	 through	 bulk	 flow	 (Qbulk	 =	 0.0016	 mL/min	 [29]).	 Volumes	 of	
distribution	of	the	brain	and	CSF	compartments	were	set	to	physiological	values	(V3	
=	0.36	mL,	V4	=	0.09	mL)	[29].	The	relationships	between	microrate	constants	(e.g.,	





log-normal	 distribution	 and	 described	 by	 an	 exponential	 error	 model.	 Additive,	
proportional	and	mixed	error	models	were	evaluated	 for	 the	residual	unexplained	




Q2 = K34 ×V3 = K43 ×V4
Qbulk = Kbulk ×V4
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parameters	was	evaluated.	IIVs,	residual	errors	and	covariates	were	included	in	the	
model	 only	 if	 they	were	 associated	with	 a	 decrease	 in	 OFV	 by	 at	 least	 3.84	 (χ2	 p	
value	 ≤ 0.05).	
The	final	PK	model	was	evaluated	by	nonparametric	bootstrap	analysis	and	
visual	 predictive	 checks	 using	 Perl-speaks-NONMEM	 (PsN	 4.2.0).	 Two	 hundred	
bootstrap	samples	were	generated	from	the	original	data	set	and	then	fitted	to	the	
final	 population	 PK	 model	 to	 obtain	 parameter	 estimates.	 The	 median	 and	 90%	
bootstrap	 confidence	 interval	 calculated	 from	 the	 successful	 bootstrap	 runs	were	
compared	 with	 final	 model	 estimates.	 For	 visual	 predictive	 checks,	 1000	
hypothetical	patient	datasets	were	simulated	using	the	parameter	estimates	of	 the	




As	 shown	 in	 Figure	 4-2,	 brain	 L-[14C]His	 concentrations	 were	 significantly	
lower	in	Pht1	KO	mice	compared	to	WT	animals	at	early	time	points	(before	10	min)	
but	less	so	in	later	ones,	suggesting	a	difference	on	the	distribution	rate	of	L-[14C]His	






A	 stepwise	 compartmental	 model	 building	 approach	 was	 performed	 to	




bootstrap	 results	 were	 listed	 in	 Table	 4-1.	 Consistent	 with	 our	 previous	
noncompartmental	 analysis	 [9],	 the	 plasma	 PK	 parameters	 of	 L-[14C]His	 were	
comparable	in	WT	and	Pht1	KO	mice.	The	total	plasma	clearance	(CL)	of	L-[14C]His	
was	0.31	mL/min,	and	its	volumes	of	distribution	in	the	central	(V1)	and	peripheral	
(V2)	 compartments	 were	 4.49	 mL	 and	 5.47	 mL,	 respectively.	 The	 distribution	




role	 as	 an	uptake	 transporter	 for	L-[14C]His	 in	 the	brain.	 	 In	 the	pilot	 study,	L-His	
concentrations	 in	brain	parenchyma	reached	a	plateau	at	20	min	post	dose,	which	
was	consistent	with	the	literature	[30].	Therefore,	we	only	characterized	the	first	30	
min	 after	 dosing.	 The	 first-order	 rate	 constant	 directing	 L-[14C]His	 from	 brain	
parenchyma	to	the	plasma	(K31)	was	fixed	as	zero	in	the	final	model.	The	impact	of	
mouse	genotype,	gender,	age	and	body	weight	on	the	PK	parameters	was	evaluated.	










residuals	 randomly	 distributed	 along	 the	 zero	 ordinate	 line	 with	 no	 obvious	
deviations.	 As	 shown	 in	 the	 visual	 predicted	 check	 plots	 (Figure	 4-4),	 observed	
concentrations	 in	 all	 of	 the	 compartments	 were	 in	 good	 agreement	 with	 the	
prediction	 intervals	 of	 1000	 simulations	 based	 on	 parameter	 estimates	 from	 the	




There	 is	 emerging	 evidence	 showing	 that	 PHT1	 plays	 an	 important	 role	 in	
the	brain	as	an	uptake	transporter.	In	particular,	the	protein	expression	of	PHT1	in	
brain	 increased	 with	 age	 in	 both	 mice	 and	 rats,	 and	 its	 function	 dominated	 the	
uptake	 of	 glycylsarcosine	 in	 brain	 slices	 [8].	 Moreover,	 our	 previous	 findings	
showed	that	PHT1	was	the	major	transporter	in	regulating	the	in	vitro	distribution	
of	 L-His	 in	 brain,	 where	 it	 accounted	 for	 50%	 of	 the	 total	 uptake	 of	 L-His	 in	
hypothalamus	slices.	In	contrast,	the	L-amino	acid	transporters	accounted	for	30%	




In	 the	present	 study,	 the	PK	properties	of	PHT1	 in	vivo	were	 characterized	
for	 the	 first	 time	 and	 several	 new	 findings	 were	 revealed.	 Specifically,	 a	 four-
compartment	 PK	 model	 was	 successfully	 developed	 to	 define	 the	 distribution	
kinetics	of	the	PHT1	substrate	L-[14C]His	in	brain.	By	comparing	wildtype	with	Pht1	
KO	mice,	we	could	quantify	the	PHT1-mediated	active	transport	of	L-[14C]His	from	
the	 plasma	 to	 brain	 in	 vivo	 with	 a	 single	Michaelis-Menten	 term	 (Vmax,PHT1	 =	 0.14	
nmoL/min,	 Km,PHT1	 =	 39.88	 μM).	 Moreover,	 the	 similar	 disposition	 kinetics	 of	 L-
[14C]His	 in	 plasma	 and	 CSF	 between	 the	 two	 genotypes	 suggested	 the	 absence	 of	
PHT1	at	the	blood-CSF	and	the	brain	parenchyma-CSF	interfaces.	
Based	 on	 the	 final	 model,	 the	 in	 vivo	 Km,PHT1	of	 L-[14C]His	 (39.88	 μM)	 was	
similar	 to	 the	 in	vitro	measurement	 of	 L-His	 (Km	 =	 17	 μM)	 in	 rat	Pht1-expressing	
Xenopus	oocytes	[6],	suggesting	the	plausibility	of	the	current	model	regarding	the	
PHT1-mediated	 plasma-to-brain	 uptake	 of	 L-His.	 This	 result	 also	 indicated	 that	
mouse	PHT1	was	a	high	affinity	transporter,	as	shown	for	the	rat	isoform	[6].		





the	 literature	values	of	0.5*10-3	to	13.4*10-3	1/min	 in	rat	[21,	31].	Thus,	 the	PHT1-
mediated	uptake	of	L-[14C]His	was	 calculated	as	23.8%	 in	vivo,	which	was	 smaller	
	 84	
than	 the	 50%	 value	 determined	 previously	 in	 vitro	 in	 mouse	 brain	 slices	 [9].	
Although	 speculative,	 this	 difference	 may	 reflect	 the	 fact	 that	 in	 vitro	 brain	 slice	
results	 are	 obtained	 from	 a	 stagnant	 system	 whereas	 in	 vivo	 brain	 results	 are	
dynamic	with	temporal	aspects	of	blood	flow	and	other	factors.		
A	 semi-mechanistic	 model	 would	 be	 more	 valuable	 if	 we	 were	 able	 to	
extrapolate	 these	 findings	 in	 mice	 to	 humans.	 Thus,	 it	 would	 be	 important	 to	
determine	the	protein	expression	levels	of	PHT1	and	related	transporters	in	human	
so	 that	 brain	 distribution	 of	 L-His	 or	 future	 PHT1-substrate	 drugs	 could	 be	
simulated.	 Moreover,	 considering	 the	 number	 of	 PHT1	 variants	 and	 their	
association	 with	 lupus	 systemic	 erythematosus	 [15-17],	 further	 investigation	 of	
PHT1	localization,	structure-function	and	regulation	in	the	brain	is	warranted.	
In	 conclusion,	 a	 semi-mechanistic	 population	 pharmacokinetic	 model	 was	
developed	in	mice	that	successfully	characterized	the	disposition	of	L-His,	a	model	
PHT1	substrate,	in	blood,	CSF	and	brain	parenchyma.	By	modeling	the	data	collected	
from	 Pht1-competent	 and	 Pht1-deficient	 mice	 simultaneously,	 we	 were	 able	 to	
quantitatively	describe	for	the	first	time	the	plasma-to-brain	uptake	of	L-His	under	
in	vivo	conditions.	This	model	may	provide	a	tool	in	predicting	the	brain	distribution	










Parameters Estimates (% RSE) 
Bootstrap estimates 
Median 90% CI 
CL (mL/min) 0.31 (10) 0.32 0.29, 0.36 
V1 (mL) 4.49 (10) 4.25 3.82, 5.35 
V2 (mL) 5.47 (16) 5.12 4.29, 6.75 
Q1 (mL/min) 2.12 (8) 2.14 1.94, 2.65 
K13 (1/min) 0.0025 (10) 0.0025  0.0021, 0.0029 
K14 (1/min) 0.0033 (26) 0.0029 0.0013, 0.0048 
K41 (1/min) 3.12 (26) 2.78 1.92, 4.31 
Km,PHT1 (µM) 39.88 (10) 39.90 39.89, 39.90 
Vmax,PHT1 (nmoL/min) 0.14 (36) 0.14 0.05, 0.22 
IIV %CV (% RSE) 
  ω (CL) 55 (28) 55 44, 69 
  ω (V1) 11 (159) 13 4, 19 
  ω (V2) 74 (33) 70 55, 87 
Residual error 
  σplasma (µM) 0.11 (6) 0.10 0.07, 0.14 
  σbrain (nmoL/g) 0.0011 (33) 0.001 0.0005, 0.0019 
  σCSF (µM) 0.014 (33) 0.013 0.009, 0.017 
CL,	 total	 plasma	 clearance;	 V1	 and	 V2,	 volumes	 of	 distribution	 in	 central	 and	





from	 plasma	 to	 brain;	 σplasma,	 σbrain	 and	 σCSF,	 residual	 error;	 IIV,	 inter-individual	
	 86	









and	 K43	 first-order	 microrate	 constants	 between	 the	 respective	


































plasma,	 brain	 parenchyma	 and	
CSF	 compartments	 of	 wildtype	
(WT)	 and	 Pht1	 knockout	 (KO)	
mice.	*p ≤ 0.05 and **p ≤ 0.01. The	
figures	 were	 adapted	 from	 a	
previous	 paper	 for	 genotype	
comparisons	[9].	
	 	
























































Figure	 4-3	 Basic	 goodness-of-fit	 plots	 of	 population	pharmacokinetic	 parameters.	
CWRES,	conditional	weighted	residual.	
	 	
















































































































































































































































































































































































































































































































































































































































































































Figure	 4-4	 Visual	 predictive	 check	 of	 the	 final	 pharmacokinetic	 model	 of	 L-
[14C]histidine	 in	 plasma,	 brain	 and	 CSF	 of	 wildtype	 (WT)	 and	 Pht1	
knockout	 (KO)	 mice,	 based	 on	 1000	 simulations.	 Observed	 data	 are	
shown	as	circles.	Solid	and	dashed	lines	represent	the	median,	and	10th	
and	90th	percentiles	of	the	observed	data.	The	semitransparent	red	field	


















































































































































































































































































































Compared	 with	 PEPT1	 and	 PEPT2,	 little	 is	 known	 about	 the	
peptide/histidine	transporter	PHT1	regarding	the	expression,	localization,	function	
and	 pharmacological	 relevance.	 Based	 on	 previous	 but	 limited	 information,	 PHT1	
protein	was	expressed	in	the	brain	and	retina	of	rat,	and	showed	high	affinity	for	L-
histidine	 (L-His).	 PHT1	 protein	 was	 also	 expressed	 in	 the	 brain	 of	 adult	 but	 not	
neonatal	rats	and	mice,	showing	a	dominant	role	in	glycylsarcosine	brain	uptake	in	








and	 protein	 levels.	 The	 transcription	 of	 several	 selected	 L-His	 amino	 acid	




and	 enzymes	 related	 to	 histamine	 production	 in	 the	 brain	 is	 needed	 in	 order	 to	
better	understand	 the	 impact	 of	Pht1	 depletion	on	 gene	 regulation,	 as	well	 as	 the	
compensatory	role	of	the	histerminergic	system.		
One	of	the	most	important	physiological	functions	of	L-His	in	the	brain	is	as	a	
precursor	 of	 histamine.	 The	 dysfunction	 of	 PHT1	 may	 contribute	 to	 the	 reduced	
levels	 of	 brain	 histamine	 under	 certain	 pathological	 conditions.	 Therefore,	




this	 dissertation,	 the	 significant	 role	 of	 PHT1	 in	 the	 brain	 entry	 of	 L-His	 was	







information	 may	 provide	 us	 an	 insight	 of	 the	 correlation	 between	 Pht1	 gene	
polymorphism	and	neurological	diseases.	
Based	on	the	substrate	specificity	study,	the	transport	of	L-His	by	PHT1	could	
be	 inhibited,	 as	 expected,	 by	 dipeptides	 (e.g.,	 carnosine	 and	 glycylsarcosine)	 and	




(L-His,	 L-lysine)	 or	 uncharged	 polar	 (L-asparagine,	 L-glutamine)	 side	 chains	 and	
PHT1	needs	further	investigation	to	test	whether	other	amino	acids,	 in	addition	to	
L-His,	 are	 substrates	 for	 PHT1.	 Pht1-transfected	 cell	 culture	 systems	 could	 be	















1	 0.37	 0.42	 0.31	 0.37	 0.05	 0.11	 0.11	 0.03	
3	 0.65	 0.59	 0.91	 0.65	 0.60	 0.21	 0.35	 0.62	
5	 0.81	 0.85	 0.72	 0.67	 0.64	 0.74	 0.89	 0.87	





1	 0.28	 0.38	 0.13	 0.17	 0.02	 0.07	 0.02	 0.01	
3	 0.45	 0.35	 0.55	 0.55	 0.23	 0.16	 0.23	 0.29	
5	 0.55	 0.58	 0.45	 0.56	 0.30	 0.61	 0.46	 0.70	





1	 0.49	 0.40	 0.66	 0.27	 0.26	 0.28	 0.20	 0.07	
3	 0.51	 1.10	 1.02	 0.87	 0.28	 0.23	 0.48	 0.42	
5	 0.88	 0.83	 1.40	 0.94	 0.92	 0.94	 0.72	 0.82	





1	 0.27	 0.38	 0.37	 0.29	 0.16	 0.20	 0.13	 0.17	
3	 1.14	 0.93	 1.13	 1.14	 0.59	 0.36	 0.52	 0.67	
5	 1.68	 1.54	 1.27	 1.31	 0.58	 1.02	 0.99	 0.85	





slices	 of	 adult	wildtype	 (WT)	 and	Pht1	 null	 (Null)	mice	 in	 the	 absence	
(control)	 or	 presence	 of	 potential	 inhibitors	 (5	 mM).	 BCH,	 2-
aminobicyclo	[2.2.1]heptane-2-carboxylic	acid;	GlySar,	glycylsarcosine.	
	 WT	 Null	
Control	 1.14	 0.93	 1.13	 1.14	 0.59	 0.36	 0.52	 0.67	
Histidine	 0.20	 0.27	 0.21	 0.15	 0.21	 0.21	 0.22	 0.17	
Glutamine	 0.17	 0.15	 0.27	 0.15	 0.21	 0.14	 0.19	 0.15	
BCH	 0.14	 0.19	 0.26	 0.15	 0.17	 0.15	 0.20	 0.18	
Lysine	 0.18	 0.19	 0.22	 0.31	 0.18	 0.19	 0.18	 0.23	
Asparagine	 0.24	 0.21	 0.22	 0.24	 0.22	 0.22	 0.24	 0.25	
Leucine	 0.79	 0.66	 0.69	 0.82	 0.36	 0.29	 0.33	 0.30	
Carnosine	 0.40	 0.72	 0.98	 0.75	 0.79	 0.40	 0.65	 0.40	









1	 2	 3	 4	 5	 6	 7	 8	 9	 10	 11	
0.5	 2.80	 3.67	 6.86	 2.06	 3.17	 2.20	 6.16	 2.19	 3.18	 3.54	 	
1.0	 1.84	 2.47	 3.33	 2.01	 1.40	 1.55	 4.90	 1.96	 2.82	 3.36	 2.92	
2.0	 1.65	 2.56	 2.84	 1.74	 1.09	 1.29	 4.21	 1.71	 2.59	 3.79	 	
5.0	 1.46	 1.74	 2.02	 1.38	 0.83	 0.73	 2.72	 1.29	 1.91	 2.29	 1.26	
10.0	 	 	 	 	 	 	 1.98	 1.07	 1.31	 1.86	 1.03	
15.0	 	 	 	 	 	 	 	 	 1.02	 1.42	 1.00	
20.0	 	 	 	 	 	 	 	 	 0.95	 1.28	 0.94	





1	 2	 3	 4	 5	 6	 7	 8	 9	 10	 11	 12	
0.5	 3.80	 	 2.47	 3.84	 6.12	 2.69	 2.74	 2.24	 4.81	 5.82	 5.20	 3.69	
1.0	 2.64	 3.52	 1.67	 2.87	 	 1.67	 2.06	 1.84	 2.39	 3.63	 4.93	 3.30	
2.0	 2.09	 2.46	 1.37	 3.04	 	 1.67	 1.84	 1.65	 2.09	 2.07	 4.14	 	
5.0	 1.85	 1.61	 0.88	 1.98	 2.75	 1.80	 1.50	 1.32	 1.37	 1.26	 	 1.69	
10.0	 	 	 	 	 2.09	 1.53	 1.20	 1.08	 1.03	 0.76	 	 1.18	
15.0	 	 	 	 	 	 	 	 	 0.63	 0.53	 1.01	 1.06	
20.0	 	 	 	 	 	 	 	 	 0.51	 0.40	 1.54	 0.93	











2.0	 0.33	 0.41	 0.40	 	 	 	 0.08	 0.25	 0.29	 	
5.0	 0.45	 0.45	 0.48	 0.33	 0.48	 0.50	 0.28	 0.29	 0.35	 0.19	
10.0	 0.64	 0.41	 0.44	 0.37	 0.43	 	 0.47	 0.42	 0.34	 0.41	
20.0	 0.42	 0.42	 0.44	 	 	 	 0.32	 0.41	 0.35	 	





2.0	 0.34	 0.50	 0.43	 	 	 	 0.21	 0.30	 0.25	 	
5.0	 0.46	 0.64	 0.52	 0.38	 0.62	 0.70	 0.38	 0.35	 0.39	 0.22	
10.0	 0.65	 0.40	 0.45	 0.42	 0.43	 	 0.47	 0.42	 0.46	 0.42	
20.0	 0.43	 0.48	 0.47	 	 	 	 0.47	 0.50	 0.45	 	





2.0	 0.58	 0.42	 0.42	 	 	 	 0.21	 0.28	 0.29	 	
5.0	 0.66	 0.68	 0.48	 0.43	 0.63	 0.60	 0.35	 0.33	 0.31	 0.22	
10.0	 0.56	 0.41	 0.53	 0.41	 0.42	 	 0.48	 0.42	 0.49	 0.41	
20.0	 0.44	 0.45	 0.50	 	 	 	 0.40	 0.39	 0.47	 	





2.0	 0.30	 0.37	 0.37	 	 	 	 0.21	 0.23	 0.31	 	
5.0	 0.54	 0.64	 0.43	 0.36	 0.59	 0.59	 0.26	 0.28	 0.37	 0.26	
10.0	 0.62	 0.40	 0.55	 0.37	 0.45	 	 0.44	 0.43	 0.39	 0.42	
20.0	 0.46	 0.52	 0.45	 	 	 	 0.42	 0.37	 0.42	 	





2.0	 0.14	 0.18	 0.17	 	 	 	 0.24	 0.14	 0.15	 	
5.0	 0.03	 0.04	 0.09	 0.12	 0.12	 0.20	 0.08	 0.10	 0.09	 	
10.0	 0.06	 0.08	 0.14	 	 	 	 0.11	 0.07	 0.09	 	
20.0	 0.12	 0.07	 0.08	 	 	 	 0.07	 0.06	 0.08	 	












Purpose	 The	 objective	 of	 this	 work	 was	 to	 characterize	 and	 compare	 the	
population	 pharmacokinetics	 (PK)	 mycophenolic	 acid	 (MPA)	 in	 adult	 lung	




patients	with	 or	without	 CF	 following	 repeated	MPA	 treatment	with	 at	 least	 a	 2-
week	 break	 between	 the	 visits.	 A	 population	 PK	 model	 was	 developed	 using	
nonlinear	mixed	effects	modeling	(NONMEM)	and	the	contribution	of	physiological	




CF	 patients	 had	 a	 slower	 absorption	 rate	 (Ka),	 and	 elevated	 CL/F	 and	 volume	 of	
	 102	
distribution	(Vd/F)	compared	with	NCF	patients.	There	is	a	significant	contribution	










in	 lung	 transplantation,	 in	 which	 approximately	 50%	 of	 all	 lung	 transplant	






all	 lung	 transplant	 indications	 [1].	 CF	 is	 caused	 by	 mutations	 in	 the	 CF	
transmembrane	 conductance	 regulator	 gene	 (CFTR)	 leading	 to	 abnormal	 sodium	
chloride	 transport	 in	 multiple	 organs	 including	 the	 gastrointestinal	 tract	 [3].	
Pancreatic	 ductal	 epithelium,	 intestinal	 epithelium,	 and	 the	 hepatobiliary	 ductal	
system	 can	 be	 affected	 by	 CFTR	 mutations	 leading	 to	 pancreatic	 insufficiency,	
	 103	
intestinal	 obstruction,	 and	 focal	 biliary	 cirrhosis	 as	 well	 as	 cholelithiasis	 and	
cholecystitis,	all	of	which	can	affect	drug	absorption	and	metabolism	[4].	 In	recent	
years,	 lung	 transplantation	 has	 been	 introduced	 as	 a	 treatment	 for	 patients	 with	
end-stage	 lung	 disease	 including	 those	 patients	 with	 CF.	 However,	 information	
concerning	the	population	PK	properties	of	MPA	in	lung	transplantation	is	 limited,	
especially	in	CF	patients.	








Adult	 lung	transplant	patients	(5	CF	and	5	NCF)	were	enrolled	 in	 this	pilot,	











S1).	 Patients	 were	 admitted	 to	 the	 clinical	 research	 unit	 after	 an	 overnight	 fast.	
Patients	had	 serial	 blood	 samples	 (5	mL	each)	drawn	at	 various	 times	 at	predose	
and	 0.5,	 1,	 2,	 3,	 4,	 6,	 8	 and	 12	 hours	 after	 the	 MMF	 morning	 dose.	 Serum	
concentrations	 of	 MPA	 were	 determined	 by	 a	 validated	 liquid	 chromatography-
tandem	 mass	 spectrometry	 method	 [5].	 Demographic	 (age,	 weight,	 gender)	 and	
clinical	 (serum	 creatinine	 (Scr),	 albumin,	 creatinine	 clearance	 (CrCL))	 data	 were	






Serum	 concentration	 versus	 time	 curves	 of	MPA	was	 initially	 fit	 to	 a	 non-
compartmental	 model,	 using	 WinNonlin	 version	 5.0.1	 (Pharsight	 Inc.,	 Mountain	
View,	CA).	Total	area	under	the	concentration-time	curve	(AUC0-12h)	was	calculated	
using	 the	 trapezoidal	 rule.	 Apparent	 oral	 clearance	 (CL/F),	 apparent	 volume	 of	
distribution	 (Vd/F),	maximum	plasma	concentration	 (Cmax)	and	 time	 to	 reach	Cmax	
(Tmax)	 were	 calculated	 using	 standard	 methods.	 Since	 the	 oral	 bioavailability	 (F)	




Population	 PK	 analysis	 was	 performed	 for	 the	 MPA	 serum	 concentrations	
from	 CF	 patients	 and	 NCF	 patients.	 Generally,	 the	 population	 PK	 modeling	 was	
carried	 out	 using	 a	 nonlinear-mixed	 effects	 modeling	 approach	 by	 NONMEM	
software	 version	 7	 (ICON	 Development	 Solutions,	 MD,	 USA).	 The	 first-order	
conditional	 estimation	 (FOCE)	 method	 with	 interaction	 was	 used	 to	 build	 the	
compartment	 models	 throughout	 the	 modeling	 procedure	 to	 estimate	 PK	
parameters	and	variability.	Model	development	was	guided	by	the	 likelihood	ratio	
test	 using	 objective	 function	 values	 (OFV),	 graphical	 goodness-of-fit	 and	 potential	
clinical	 plausibility.	 Graphical	 and	 statistical	 analyses	 of	 NONMEM	 output	 and	
simulations	 were	 performed	 using	 S-Plus	 6.2	 and	 R	 version	 3.0.2	 with	 Xpose	
package.	The	compartmental	pharmacokinetic	model	was	built	 through	a	stepwise	
approach.		
First,	one-,	 two-	and	 three-compartment	models	were	performed	using	 log-
transformed	 or	 non-transformed	 serum	 concentration	 data.	 The	 models	 with	 or	
without	a	lag	time	(tlag)	were	also	evaluated.	First-order	absorption	and	elimination	
were	assumed	in	our	analysis.	Basic	pharmacokinetic	parameters	were	estimated	by	
NONMEM	 using	 conventional	 equations,	 including	 absorption	 rate	 constant	 (Ka),	
apparent	 volume	of	 distribution	 of	 each	 compartment	 (Vi/F,	 i	 =	 1,	 2,	 3),	 apparent	






!! = !×!"# !! 	
where	!! 	represents	 the	 parameter	 estimate	 for	 the	 ith	 individual,	!	is	 the	 typical	
individual,	and	!! 	is	the	IIV	term.	The	values	of	!! 	were	assumed	to	follow	a	normal	
distribution	with	mean	of	zero	and	estimated	variance	of	ω2.		
Additive,	 proportional	 and	 mixed	 error	 models	 were	 evaluated	 for	 the	
residual	unexplained	variability	using	the	following	equations:	
! = !"#$% + !	
! = !"#$%× 1+ ! 	
! = !"#$%× 1+ !! + !!	
where	 Y	 is	 the	 observed	 concentration,	 IPRED	 is	 the	 individual	 prediction	 and	 ε	
represents	the	residual	variability.	The	values	of	ε	follow	a	normal	distribution	with	
mean	of	zero	and	variance	of	σ2.		
The	 impact	 of	 patient	 demographic	 and	 clinical	 covariates	 on	













were	 summarized	 in	 Supplementary	 Table	 S1.	 CF	 patients	 recruited	 in	 this	 study	
were	significantly	younger	than	NCF	patients	and	had	lower	serum	albumin	levels.	
MPA	PK	parameters	were	estimated	by	both	non-compartmental	analysis	and	non-
linear	 mixed	 effects	 modeling	 (NONMEM),	 and	 the	 results	 were	 summarized	 in	
Table	 B-1	 and	 B-2.	 The	MPA	 AUCs	 in	 lung	 transplantation	 patients	 with	 CF	 (133	
μM×hr)	and	without	CF	(175	μM×hr)	were	comparable	to	those	reported	previously	
in	the	literature	[5].	Based	on	the	results	of	non-compartmental	analysis,	it	appears	
that	 the	 CF	 group	 had	 a	 lower	 MPA	 Cmax	 and	 a	 longer	 Tmax,	 suggesting	 a	 slower	
absorption	 in	 those	patients	 (Table	B-1).	 In	addition,	both	MPA	CL/F	and	Vd/F	 in	
the	CF	group	appear	higher	than	the	corresponding	values	in	the	NCF	group	(Table	
B-1).	When	MPA	PK	parameters	from	visits	1,	2	and	3	were	compared,	an	increase	of	
MPA	 CL/F	 with	 time	 was	 observed	 in	 the	 CF	 patients,	 while	 no	 obvious	 time	
dependency	of	other	parameters	were	observed.	The	 contribution	of	 time	 to	MPA	
CL/F	in	CF	patients	was	further	evaluated	during	population	PK	model	development	
using	NONMEM.		
During	 the	 population	 PK	 analysis,	MPA	 serum	 concentration-time	 profiles	
for	 both	 CF	 and	 NCF	 patients	 were	 best	 described	 by	 a	 two-compartment	model	
with	 first-order	 absorption.	 A	 proportional	 error	 model	 was	 selected	 in	 the	 final	
model	 for	 the	 residual	 unexplained	 variability.	 The	 contribution	 of	 CF	 disease,	






covariate	 for	CL/F	 in	 the	CF	patients	significantly	 improved	model	prediction	(p	≤	
0.05),	and	increase	of	CL/F	with	time	in	each	CF	patient	was	shown	in	Fig.	B-1.	The	
basic	 goodness-of-fit	 plots	 for	 the	 final	 model	 was	 presented	 in	 Fig.	 B-2.	 	 One	
thousand	 hypothetical	 patient	 data	 sets	 were	 simulated	 using	 the	 parameter	
estimates	 from	 the	 final	 model	 and	 the	 plot	 was	 presented	 in	 Fig.	 B-3.	 The	 95%	
prediction	 intervals	 of	 the	 median,	 5th	 and	 95th	 percentiles	 of	 simulated	 results	
could	cover	the	observed	data	percentiles.	
DISCUSSION	
MMF	 is	 widely	 used	 in	 combination	with	 calcineurin	 inhibitors	 to	 prevent	
acute	 allograft	 rejection	 in	 solid	 organ	 transplantation.	 Its	 PK	 characteristics	 are	
well	 investigated	 in	 renal	 and	hepatic	 transplant	 recipients	with	 therapeutic	MPA	
AUC	 ranging	 from	 30	 -	 60	mg×hr/L	 as	 reported	 in	 the	 literature	 [5-7].	 In	 recent	
years,	 lung	 transplantation	 has	 been	 introduced	 as	 a	 treatment	 for	 patients	 with	
end-stage	 lung	disease	 including	 those	patients	with	CF.	However,	 information	on	
MPA	 population	 PK	 in	 lung	 transplantation	 is	 limited,	 especially	 in	 CF	 patients.	
Meanwhile,	highly	variable	and	unpredictable	PK	of	MPA	in	solid	organ	transplant	





patients.	 In	 general,	 the	 disposition	 of	 many	 drugs	 is	 altered	 in	 CF	 patients,	 and	
changes	 in	PK	can	 include	decreased	absorption,	 increased	volume	of	distribution,	
decreased	 plasma	 concentration,	 and	 enhanced	 renal	 and	 sometimes	 non-renal	
elimination	 of	 drugs.	 In	 our	 study,	 alterations	 in	 MPA	 absorption,	 and	 possibly	
distribution	and	elimination	were	also	observed	in	the	CF	patients.	Patients	with	CF	
disease	 had	 a	 slower	 absorption	 rate	 (mean	Ka	 =	 1.05	 hr-1),	 along	with	 enhanced	
oral	clearance	(mean	CL/F	=	17.83	L/hr)	and	volume	of	distribution	(mean	V2/F	=	
83.68	L,	V3/F	=	151.6	L)	 (The	mean	value	of	MPA	PK	parameters	 in	 the	CF	group	
were	calculated	based	on	the	individual	PK	parameters	of	all	visits	estimated	from	





different	 calculation	 algorithms	 being	 used	 by	 NONMEM	 and	 WinNonlin.	 For	
WinNonlin,	CL/F	was	mainly	based	on	the	fit	of	terminal	phase,	while	for	NONMEM,	
CL/F	 was	 determined	 according	 to	 the	 overall	 drug	 concentration	 profile.	 The	
reduced	Ka	of	MPA	in	CF	patients	is	possibly	due	to	gastrointestinal	malabsorption,	
intestinal	obstruction,	focal	biliary	cirrhosis,	and	pancreatic	insufficiency	associated	
with	 CF	 disease	 [11-14].	 MPA	 is	 primarily	 eliminated	 by	 hepatic	 oxidative	
metabolism	 followed	 by	 conjugation	 and	 biliary	 excretion,	 and	 increased	 hepatic	
metabolism	has	been	 reported	previously	 in	 the	 literature	 for	 several	other	drugs	
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(e.g.,	theophylline,	 lorazepam,	ibuprofen,	tobramycin,	doxycycline)	in	patients	with	
CF	 [15-19].	 The	 altered	 CL/F	 of	MPA	 in	 CF	 patients	may	 be	 explained	 by	 several	
reasons.	First,	the	CF	group	had	a	significantly	lower	serum	albumin	level	than	the	
NCF	group	 (Supplementary	Table	S1).	 In	 the	blood,	 approximately	97%	of	MPA	 is	
bound	to	serum	albumin	and	other	plasma	proteins,	and	albumin	concentration	 is	
positively	 correlated	 with	 MPA	 plasma	 protein	 binding	 [20].	 The	 hepatic	
metabolism	of	MPA	is	directly	affect	by	its	protein	binding	ratio	[21];	in	other	words,	
a	 lower	 albumin	 concentration	 observed	 in	 CF	 patients	 may	 explain	 the	
enhancement	of	CL/F	for	MPA	if	the	free	fraction	of	MPA	in	serum	is	increased	[22,	
23].	Second,	 if	 the	 intrinsic	hepatic	clearance	 increased	 in	CF	patients,	an	elevated	
CL/F	 might	 also	 be	 observed.	 Third,	 MPA	 is	 a	 substrate	 of	 p-glycoprotein,	 and	
elevated	p-glycoprotein	level	in	the	CF	patients	was	reported	previously,	which	may	
help	 to	explain	 the	decrease	 in	oral	 availability,	 and	 increase	 in	CL/F	and	Vd/F	of	
MPA	 [24,	 25].	 Finally,	 the	 higher	 CL/F	 value	 may	 be	 explained	 by	 the	 reduced	
bioavailability	 due	 to	 complications	 of	 CF	 as	mentioned	 previously,	 which	 can	 be	
confirmed	 by	 studying	 the	 kinetics	 after	 intravenous	 dosing.	 Similarly,	 the	 higher	
Vd/F	 of	 MPA	 in	 CF	 patients	 may	 also	 be	 explained	 by	 relatively	 lower	 plasma	
albumin	 level	 and	 lower	 oral	 bioavailability	 compared	 with	 the	 NCF	 patients.	 In	
addition,	 a	 lower	 free	 fraction	 of	MPA	 in	 the	 tissues	 of	 CF	 patients	may	 increase	
Vd/F,	as	more	drug	molecules	are	bound	to	peripheral	tissues.			
A	significant	contribution	of	time,	associated	with	MPA	CL/F	in	the	CF	group,	





improved	 model	 prediction.	 However,	 incorporating	 time	 for	 CL/F	 in	 the	 NCF	





the	 differences	 of	 MPA	 PK	 parameters	 in	 the	 CF	 and	 NCF	 patients	 suggest	 that	
therapeutic	 drug	 monitoring	 of	 MPA	 may	 be	 needed	 after	 lung	 transplantation,	
especially	for	the	CF	patients,	to	help	reduce	the	risk	of	treatment	failure	and	acute	
post-transplant	rejection	[1,	28,	29].		
In	 conclusion,	 the	 population	 PK	 model	 developed	 from	 our	 study	
successfully	 characterizes	 the	 absorption,	 distribution,	 and	 elimination	 of	MPA	 in	
lung	 transplant	 recipients	 with	 or	 without	 CF	 disease.	 The	 decrease	 of	 MPA	
absorption	 and	 increase	 of	 both	 apparent	 oral	 clearance	 (CL/F)	 and	 volume	 of	










Fig.	 B-1	 Changes	 of	 apparent	 oral	 clearance	 corrected	 by	 body	 weight	 (CL/F)	 in	
each	 cystic	 fibrosis	 patient	 with	 time	 based	 on	 population	
pharmacokinetic	model.	
	 	


















Fig.	 B-2	 Basic	 goodness-of-fit	 plots	 of	 population	 pharmacokinetic	 parameters	 in	
two	 groups	 of	 patients.	 PRED	 population	 predicted	 mycophenolic	 acid	
(MPA)	concentration	(μM),	DV	observed	MPA	concentration	(μM),	 IPRED	
individually	 predicted	 MPA	 concentration	 (μM),	 CWRES	 conditional	
weighted	residual	
	 	




















































acid	 (MPA)	 in	 patients	 based	 on	 1000	 simulations.	 Observed	 data	 are	
shown	as	dots.	Solid	and	dashed	lines	represent	the	median,	5th	and	95th	
percentiles	of	observed	data.	Semitransparent	red	field	represents	the	95%	




















0 2 4 6 8 10 12
	 115	
	





































(hr)	 1.14	 82	 2.07*	 73	
Cmax	(μM)	 44.9	 81	 25.0*	 37	
Cmax
	
/(Dose/100)	 2.63	 NA	 1.24*	 NA	
AUC0-12h	(μM×hr)	 175	 54	 133*	 35	
AUC0-12h	/(Dose/100)	 15.9	 NA	 11.6*	 NA	
Vd/F	(L)	 78.0	 58	 120*	 69	
CL/F	(L/hr)	 7.32	 38	 12.7*	 52	







with	 time-dependent	apparent	oral	 clearance	 (CL/F)	 for	 cystic	 fibroses	
(CF)	patients	
Parameter	 Estimates	(%RSE)	 IIV	%CV	(%RSE)	
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compare	 the	 population	 pharmacokinetics	 (PK)	 of	 the	 immunosuppressant	
mycophenolic	 acid	 (MPA),	 and	 its	 glucuronide	 metabolite	 (MPAG)	 in	 adult	 lung	
transplant	 recipients	 with	 and	 without	 CF	 (NCF)	 following	 repeated	 oral	
administration	of	the	prodrug	mycophenolate	mofetil	(MMF).		
A	 population	 PK	 model	 was	 developed,	 with	 simultaneously	 modeling	 of	
MPA	 and	 MPAG,	 using	 nonlinear	 mixed	 effects	 modeling.	 MPA	 and	 MPAG	 serum	
concentration-time	 data	 were	 adequately	 described	 by	 a	 compartmental	 model	
including	 enterohepatic	 recirculation	 (EHR).	 Both	 MPA	 and	 MPAG	 apparent	
clearance	values	were	significantly	elevated	(>	65%)	in	CF	patients	(24.1	and	1.95	
L/hr,	respectively)	compared	to	the	values	in	the	NCF	patients	(14.5	and	1.12	L/hr,	
respectively),	 suggesting	 a	 notable	 influence	 of	 CF	 on	 MPA	 absorption	 and	
disposition.		
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The	 population	 PK	 model	 developed	 from	 our	 study	 successfully	
characterized	 the	 absorption,	 distribution,	 elimination	 and	 EHR	 of	 MPA	 and	 the	
metabolite	MPAG	in	lung	transplant	recipients	with	or	without	CF.	This	model	may	
help	 to	 further	 understand	 the	 impact	 of	 CF	 to	 the	 overall	 clinical	 effects	 of	MPA	
therapy	including	immunosuppression	and	gastrointestinal	side	effects.	
INTRODUCTION	
Mycophenolate	 mofetil	 (MMF)	 is	 an	 immunosuppressant	 prodrug	 of	
mycophenolic	 acid	 (MPA).	 It	 has	 been	 used	 widely	 for	 the	 prophylaxis	 of	 acute	
allograft	 rejection	 in	 solid	 organ	 transplantation.	 For	 adult	 lung	 transplant	
recipients,	 MMF	 combined	 with	 tacrolimus	 accounts	 for	 approximately	 50%	 of	
maintenance	immunosuppressant	therapy	[1-3].	
After	 oral	 administration,	 MMF	 was	 rapidly	 and	 nearly	 completely	
hydrolyzed	 to	 the	 active	 metabolite	 MPA	 resulting	 in	 undetectable	 MMF	 level	 in	
plasma	[4].	The	MPA	was	then	primarily	(~90%)	converted	to	a	stable	metabolite,	
MPA-7-O-glucuronide	 (MPAG)	 in	 the	 body	 [3,	 5].	 MPAG	 is	 a	 pharmacologically	
inactive	 metabolite	 that	 may	 undergo	 enterohepatic	 recirculation	 (EHR),	 and	
converted	 back	 to	 MPA,	 contributing	 approximately	 40%	 of	 MPA	 area	 under	 the	
concentration-time	curve	(AUC)	[5,	6].	EHR	of	MPAG	may	prolong	the	exposure	of	
MPA	 in	 intestinal	 epithelium	 [7],	 which	 is	 closely	 linked	 to	 significant	
gastrointestinal	 side	 effects	 such	 as	 leukopenia	 and	 diarrhea	 [8,	 9].	 Therefore,	 a	




Cystic	 fibrosis	 (CF)	 is	 one	 of	 the	 top	 three	 leading	 causes	 for	 lung	
transplantation	 which	 is	 caused	 by	 a	 defect	 in	 CF	 transmembrane	 conductance	
regulator	 (CFTR)	 in	 epithelial	 cells	 [10].	 Lung	 transplantation	 may	 eventually	 be	
required	due	to	progressive	respiratory	 insufficiency,	 in	order	to	 improve	survival	
and	 quality	 of	 life	 in	 patients	with	 end-stage	 CF	 [10].	 Altered	 pathophysiology	 in	
epithelial	 cells	 of	multiple	 organs,	 including	 gastrointestinal	 tract,	 heart,	 liver	 and	
kidney,	may	affect	 the	disposition	and	 increase	 inter-individual	 variability	 (IIV)	of	
PK	parameters	of	drugs	administered	to	CF	patients	through	various	complications,	
including	 gastric	 acid	 hypersecretion,	 bile	 acid	 malabsorption,	 proximal	 small	
intestinal	mucosal	 injury,	 hypoalbuminaemia,	 hepatobiliary	 dysfunction	 and	 renal	
dysfunction	 [2,	 11].	 In	 addition,	 CF	disease	may	 also	 influence	 the	EHR	of	 several	
substrates.	 For	 example,	 a	 preclinical	 study	 showed	 that	 CFTR	deficient	mice	 had	
disrupted	 EHR	 of	 bile	 acids,	 owing	 to	 defects	 in	 gallbladder	 emptying	 [12].	 	 Oral	
vitamin	D	supplementation	also	showed	less	effectiveness	in	CF	patients	which	was	
caused	by	interruption	of	the	EHR	[13].	However,	PK	studies	on	MPA	and	the	EHR	of	




MPA	 than	NCF	patients.	However,	 in	 this	 study,	 the	 enterohepatic	 recirculation	of	




to	 better	 integrate	 this	 complexity.	 Therefore,	 the	 objective	 of	 this	 work	 was	 to	
characterize	and	compared	the	EHR	process	in	this	specific	disease	population	with	
other	 disease	 populations,	 and	 potentially	 provide	 useful	 information	 for	 MPA	
pharmacotherapy	and	gastrointestinal	toxicity.	In	this	study,	a	population	PK	model	
was	 developed,	with	 simultaneously	modeling	 of	MPA	 and	MPAG	 using	 nonlinear	








as	 described	 previously	 [14,	 15].	 This	 study	 was	 performed	 at	 the	 University	 of	
Michigan	Medical	 Clinical	 Research	Unit.	 Briefly,	 inclusion	 criteria	were:	 1)	 18-70	
years	of	age;	2)	>1	year	post-transplant;	3)	no	evidence	of	acute	rejection	at	1	year	
post-transplant	 biopsy	 or	 within	 three	 months	 of	 study	 entry;	 4)	 stable	




data	points	 from	10	patients	were	available	 for	PK	analysis.	Five	of	 these	patients	
underwent	 transplantation	 owing	 to	 cystic	 fibrosis	 and	 the	 other	 five	 owing	 to	
	 126	
idiopathic	pulmonary	fibrosis,	emphysema,	or	pulmonary	hypertension.		All	patients	
were	maintained	on	MMF,	 tacrolimus	and	prednisone,	and	received	 insulin	due	 to	
diabetes	as	well	as	a	proton	pump	inhibitor	for	gastric	acid	suppression.		
Patients	were	given	repeated	daily	oral	doses	of	MMF	(500	mg,	750	mg,	1000	mg	or	
1500	mg)	with	 12-hour	 dosing	 interval.	MMF	 dose	was	 determined	 based	 on	 the	
individual	 patient’s	 immunological	 risk	 and	 clinical	 response	 by	 their	 transplant	
team.	 	 The	 dose	 was	 not	 altered	 for	 this	 study	 and	 patients	 were	maintained	 on	
same	 doses	 throughout	 the	 study.	 After	 at	 least	 one-year	 post-transplant,	 three	
separate	 12-hr	 PK	 visits	 were	 conducted	 for	 each	 patient	 with	 at	 least	 a	 2-week	
break	between	the	visits.	There	was	no	significant	difference	on	sampling	occasions	
since	 the	 start	 of	 the	 treatment	 or	 since	 the	 first	 PK	 visit	 between	 CF	 and	 NCF	
groups.	Serial	blood	samples	were	drawn	at	predose	and	0.5,	1,	2,	3,	4,	6,	8	and	12	
hours	 after	 the	 MMF	morning	 dose.	 No	 concomitant	 medication	 alterations	 were	
made	during	the	PK	visits.	Time	points	for	blood	sampling	were	determined	in	order	
to	characterize	the	absorption	phase,	second	peak	of	MPA,	and	the	disposition	phase	
based	 on	 previous	 knowledge	 [5].	 Serum	 concentrations	 of	MPA	 and	MPAG	were	
determined	 by	 a	 validated	 liquid	 chromatography-tandem	 mass	 spectrometry	
method	 as	 previously	 described	 [15].	 The	method	was	 validated	 as	 stated	 in	 the	
literature	 [16].	The	 inter	 and	 intra-day	precision	were	<	11%,	and	 the	bias	was	<	
16%.	 Demographic	 (age,	 weight,	 gender)	 and	 clinical	 (serum	 creatinine	 (Scr),	
albumin,	 creatinine	 clearance	 (CLcr))	 data	 were	 collected	 and	 summarized	 in	 a	
previous	paper	[14].Non-compartmental	analysis	(NCA)	of	pharmacokinetics	
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Serum	 concentration	 versus	 time	 curves	 of	 MPA	 and	 MPAG	 were	 initially	
analyzed	by	a	non-compartmental	approach	using	Phoenix/WinNonlin	version	6.4	
(Pharsight	 Inc.,	 Mountain	 View,	 CA).	 Steady-state	 area	 under	 the	 serum	
concentration-time	curve	(AUC(0-12h))	was	calculated	over	the	12-hr	dosing	interval	
by	trapezoidal	rule	and	normalized	by	dose.	Dose	normalized	trough	concentration	
(Ctrough),	maximum	serum	concentration	 (Cmax)	 and	 time	 to	 reach	Cmax	 (Tmax)	were	
estimated	by	visual	inspection.		
Population	pharmacokinetics	modeling	
The	 population	 PK	 model	 with	 simultaneous	 modeling	 of	 MPA	 and	 MPAG	
was	 developed	 with	 nonlinear	 mixed	 effects	 modeling	 by	 NONMEM	 software	
version	7	 (ICON	Development	 Solutions,	MD,	USA).	Model	 structure	 selection	was	
guided	by	the	likelihood	ratio	test	using	objective	function	values	(OFV),	diagnostic	
plots,	 and	 potential	 clinical	 plausibility.	 Graphical	 and	 statistical	 analyses	 of	
NONMEM	output	and	simulations	were	performed	using	R	version	3.2.2	with	Xpose	
version	4.5.3.	
MPA	 and	 MPAG	 serum	 concentration-time	 data,	 after	 MMF	 oral	
administration,	 were	 adequately	 described	 by	 a	 model	 including	 first-order	
absorption	 of	 MPA	 from	 the	 gastrointestinal	 tract	 (GIT),	 central	 and	 peripheral	
compartments	 for	MPA	 disposition,	 and	 a	 compartment	 for	MPAG	 formation	 and	
enterohepatic	recirculation	(EHR)	(Figure	C-1).	Several	assumptions	were	made	in	
model	development:	(1)	the	conversion	from	MMF	to	MPA	was	rapid	and	complete	
prior	 to	 reaching	 the	 systemic	 circulation;	 (2)	 the	 fraction	of	MPA	metabolized	 to	
MPAG	was	fixed	(90%)	based	on	literature	information	[5];	and	(3)	all	distribution	
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a	 log-normal	 distribution	 and	 described	 by	 an	 exponential	 error	model.	 Additive,	
proportional	and	mixed	error	models	were	evaluated	 for	 the	residual	unexplained	
variability	using	the	following	equations:	
Y = F + ε
Y = F × (1+ ε )
Y = F × (1+ ε1)+ ε2
	
where	Y	 is	 the	 observed	 concentration,	 F	 is	 the	 individual	 prediction	 and	 ε	 is	 the	
residual	variability.	The	impact	of	patient	demographic	and	clinical	covariates	on	PK	
parameters	was	evaluated.	IIVs,	residual	errors	and	covariates	were	included	in	the	
model	 only	 if	 they	were	 associated	with	 a	 decrease	 in	OFV	by	 at	 least	 3.84	 (χ2	 p-
value	≤	0.05).		
The	 impact	 of	 patient	 demographic	 and	 clinical	 covariates	 on	 Due	 to	 the	
limited	 number	 of	 patients	 included	 in	 this	 study	 (n=10),	 we	 had	 difficulty	 in	
estimation	of	the	IIV	for	several	PK	parameters.	Serial	values	for	IIV	were	tested	(0-




visual	 predictive	 checks	 using	 Perl-speaks-NONMEM	 (PsN	 4.2.0).	 The	 original	
dataset	 was	 resampled	 with	 100	 replicate	 datasets	 and	 the	 medians	 and	 90%	
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confidence	 intervals	 of	 the	 parameter	 estimates	 from	 bootstrap	 samples	 were	
compared	with	final	model	estimates.	For	visual	predictive	checks,	500	hypothetical	
patient	datasets	were	 simulated	using	 the	parameter	estimates	of	 the	 final	model.	
The	 95%	 prediction	 intervals	 for	 the	 simulated	 median,	 5th	 and	 95th	 percentiles	
were	 calculated	 and	 compared	 with	 the	 observed	 data	 points	 of	 MPA	 or	 MPAG,	
respectively.	
RESULTS		
Dose	 normalized	 Cmax	 and	 AUCss	 values	 of	 MPA	 and	 MPAG,	 and	 the	
corresponding	Tmax	calculated	by	NCA,	for	each	clinical	visit	are	presented	in	Figure	
C-2.	 The	 Bland-Altman	 plot	 of	 the	 difference	 on	 dose	 normalized	 area	 under	 the	
serum	concentration-time	curve	(AUC)	between	CF	and	NCF	patients	was	shown	in	





disease.	 Ctrough	 values	 were	 also	 lower	 in	 CF	 patients,	 but	 only	 showed	 statistical	
significance	for	MPAG.	
Serum	 MPA	 and	 MPAG	 concentration-time	 profiles,	 after	 MMF	 oral	
administration,	were	adequately	described	by	 the	compartmental	model	 shown	 in	
Figure	C-1.	A	mixed	error	model	with	both	additive	and	proportional	 components	
was	 selected	 as	 the	 final	 model	 for	 the	 residual	 unexplained	 variability.	 The	
estimated	 rate	 constant	 describing	 biliary	 excretion	 and	 EHR	 of	 MPAG	 (K41)	 is	
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comparable	 to	 literature	 values	 [17].	 CF	 disease	 was	 included	 as	 a	 covariate	 for	
CLMPA/F	in	the	final	model	based	on	its	statistically	significant	contribution		(Table	
C-2).	
For	 model	 diagnosis,	 goodness-of-fit	 plots	 (Figure	 C-3)	 did	 not	 show	
systematic	bias	for	the	PK	model	predictions.	As	shown	in	the	visual	predicted	check	






MPAG	 is	 a	 major	 metabolite	 of	 MPA	 in	 human.	 Although	 MPAG	 may	 not	
directly	 contribute	 to	 the	 immunosuppression	 effect,	 it	 competes	 with	 MPA	 at	




has	 been	 estimated	 that,	 on	 average,	 enterohepatic	 recycling	 contributes	
approximately	40%	(range	10–60%)	to	MPA	exposure	[5].	 	Due	to	the	presence	of	
EHR,	 the	 exposure	 of	 MPA	 intestinal	 epithelium	was	 prolonged	 and	 this	 effect	 is	
closely	linked	with	side	effects	such	as	leukopenia	and	diarrhea	[7-9].	Therefore,	a	
better	 understanding	 of	 the	 PK	 associated	with	MPAG	EHR	 is	 needed	 considering	





patients	 with	 CF	 disease	 [3].	 In	 the	 present	 study,	 a	 population	 PK	 model	 was	
developed	 that	 successfully	 characterized	 the	 absorption,	 distribution,	 elimination	
and	EHR	of	both	MPA	and	MPAG	 in	 lung	 transplant	 recipients	with	or	without	CF		
(Figure	 C-1).	 CF	was	 identified	 as	 a	 covariate	 for	 CLMPA/F	 in	 our	 current	work.	 A	
significant	 decrease	 of	 MPA	 absorption	 and	 increase	 of	 both	 MPA	 and	 MPAG	
apparent	 clearance	 was	 identified	 in	 the	 CF	 patients,	 indicating	 the	 urgency	 of	
personalized	 medicine	 in	 MPA	 immune-suppression	 therapy	 especially	 for	 those	
patients	with	CF	disease.	
The	model	 estimated	 population	means	 of	 the	 absorption	 rate	 constant	 Ka	
(2.36	 h-1),	 apparent	 clearance	 CLMPA/F	 (14.5	 L/hr),	 and	 volumes	 of	 distribution	
(VC,MPA/F	 =	 42.1	 L,	 VP,MPA/F	 =	 402	 L)	 in	 the	 NCF	 group	 are	 close	 to	 the	 values	
reported	 in	 the	 literature	 (Ka:	 2.27	 -	 4.10	 h–1,	 CL/F:	 11.9	 -	 33.0	 L/hr,	 V/F:	 10.3	 –	
631.8	L)	[19,	20].	Similarly,	the	population	means	of	MPAG	CLMPAG/F	(1.12	L/hr)	and	
VMPAG/F	 (8.9	 L)	 from	 our	 model	 estimation	 were	 also	 consistent	 with	 literature	
values	as	reported	previously	(CL/F	=	1.12	–	4.75	L/hr,	V/F	=	3.92	-	8.91	L)	[6,	17-
22].	 Shrinkage	 values	 of	 CLMPA/F,	 Vc/F,	 Vp/F,	 Q/F,	 Ka,	 CLMPAG/F,	 VMPAG/F,	 K41	 and	
residual	errors	were	3.9%,	3.8%,	61.6%,	76.2%,	14.6%,	2.6%,	2.6%,	55%,	2.7%	and	
2.7%,	respectively.	Among	these	numbers,	the	shrinkage	values	of	Vp/F,	Q/F	and	K41	
were	 higher	 than	 30%,	 which	 could	 be	 an	 issue	 when	 data	 become	 sparse	 and	










CF	 is	 a	 genetic,	 autosomal	 recessive	 disorder,	 which	 leads	 to	 reduced	
mucociliary	clearance	and	an	increased	risk	of	infections	in	the	lungs.	As	the	disease	
progresses,	 bilateral	 lung	 transplantation	 becomes	 a	 viable	 treatment	 option.	
Besides	the	lungs,	CF	affects	the	gut	resulting	in	gastrointestinal	(GI)	malabsorption	
and	pancreatic	 insufficiency	and,	 therefore,	may	alter	 the	disposition	of	both	MPA	
and	MPAG	in	lung	transplant	recipients	with	CF	disease	following	the	treatment	of	
the	 immunosuppressant	 MMF.	 CF	 can	 affect	 the	 disposition	 of	 drugs	 in	 various	
aspects	including	decreased	absorption,	increased	volume	of	distribution,	decreased	
plasma	concentration,	and	enhanced	elimination	 [25-28].	 In	 the	present	study,	we	
have	found	a	>44%	decrease	of	MPA	Cmax,	AUC,	and	the	absorption	rate	constant	Ka,	












urine	 via	 glomerular	 filtration	 and/or	 tubular	 secretion	 [2,	 5],	 therefore,	 renal	
function	may	influence	the	pharmacokinetics	of	MPAG	to	some	extent	[5].	Changes	
in	 the	 renal	 clearance	 of	 drugs	 in	 CF	 patients	 have	 been	 widely	 studied	 with	
conflicting	 results	 reported	 in	 the	 literature	 [11].	 In	 our	 current	 study,	 a	 linear	
correlation	 between	 the	 MPAG	 apparent	 clearance	 and	 the	 creatinine	 clearance	





In	 conclusion,	 the	 population	 PK	 model	 developed	 from	 our	 study	
successfully	characterized	the	absorption,	distribution,	elimination	and	EHR	of	MPA	
and	 the	 metabolite	 MPAG	 in	 lung	 transplant	 recipients	 with	 or	 without	 CF.	 This	
model	may	help	to	 further	understand	the	contribution	of	both	MPA	and	MPAG	to	
the	 overall	 clinical	 effects	 of	 MPA	 therapy	 including	 immunosuppression	 and	
gastrointestinal	side	effects,	and	could	potentially	be	used	to	project	the	appropriate	
dose	 of	 MMF	 to	 achieve	 the	 targeted	 MPA	 efficacious	 exposure	 and	 the	
	 134	











mycophenolic	 glucuronide	 (MPAG).	 CLMPA/F	 and	 CLMPAG/F,	 apparent	
clearance	of	MPA	and	MPAG;	Vc,MPA/F	and	Vp,MPA/F,	apparent	volume	of	
distribution	of	MPA	 in	 central	 and	peripheral	 compartments;	VMPAG/F,	
apparent	 volume	 of	 distribution	 of	 MPAG;	 Q/F,	 apparent	
compartmental	 clearance	 between	 the	 MPA	 central	 and	 peripheral	
compartments;	Ka,	absorption	rate	constant	of	MPA;	Fm,	fraction	of	MPA	





Figure	 C-2.	 Comparison	 of	 pharmacokinetic	 parameters	 between	 patients	 with	
cystic	fibrosis	(CF)	or	without	the	disease	(NCF)	by	visit,	as	determined	
by	 non-compartmental	 analysis.	 AUCss,	 steady-state	 area	 under	 the	
serum	 concentration-time	 curve,	 normalized	 by	 1000	mg	 dose;	 Cmax,	


















Figure	 C-4.	 Visual	 predictive	 check	 of	 the	 final	 pharmacokinetic	 model	 of	
mycophenolic	 acid	 (MPA)	 and	 metabolite	 (MPAG)	 in	 patients	 with	
cystic	 fibrosis	 (CF)	 or	 without	 the	 disease	 (NCF)	 based	 on	 500	
simulations.	Observed	data	are	shown	as	dots.	Solid	and	dashed	lines	







Figure	 C-5.	 Linear	 correlation	 between	 the	 mycophenolic	 glucuronide	 (MPAG)	











		 All	 NCF	 CF	
MPA	 	 	 	
Ctrough/dose	(μM/mmol)	 4.83	(4.33)	 6.23	(5.74)	 3.43	(1.25)	
AUC(0-12h)/dose	(μM*hr/mmol)	 138	(51.4)	 159	(50.7)	 116*	(38.1)	
MPAG	 	 	 	
Ctrough/dose	(μM/mmol)	 38.7	(16.1)	 46.4	(16.73)	 31.1*	(11.6)	
AUC(0-12h)/dose	(μM*hr/mmol)	 1476	(1240)	 1817	(1657)	 1135*	(436)	
MPA,	 mycophenolic	 acid;	 MPAG,	 MPA	 glucuronide	 metabolite;	 Ctrough,	 trough	













NCF	 14.5	(16)	 12.5	 9.7,	21.7	
CF	 24.1	(19)	 20.0	 11.2,	51.7	
		Vc,MPA/F	(L)	 46.2	(33)	 51.8	 20.9,	102.2	
		Vp,MPA/F	(L)	 401.0	(16)	 403.4	 354.7,	452.5	
		Q/F	(L/hr)	 13.3	(15)	 14.8	 4.3,	40.4	
		Ka	(hr-1)	 1.4	(44)	 1.5	 0.5,	3.5	
		CLMPAG/F	(L/hr)	 1.4	(6)	 1.4	 1.1,	1.8	
		VMPAG/F	(L)	 9.7	(16)	 7.7	 6.3,	15.0	
		K41	(hr-1)	 0.09	(20)	 0.07	 0.04,	0.21	
IIV	%CV	(%RSE)	
		ω	(CLMPA/F)	 28	(43)	 25	 16,	36	
		ω	(Vc,MPA/F)	 73	(71)	 74	 66,	123	
		ω	(Ka)	 107	(139)	 89	 32,	155	
Residual	error	
		σ1	(additive)	(μM)	 17	(29)	 17	 2,	33	
		σ2	(proportional)	%CV	 24%	(15)	 0.06	 0.04,	0.08	
CLMPA/F	and	CLMPAG/F,	apparent	clearance	of	MPA	and	MPAG;	Vc,MPA/F	and	Vp,MPA/F,	
apparent	 volume	 of	 distribution	 of	MPA	 in	 central	 and	 peripheral	 compartments;	
VMPAG/F,	 apparent	 volume	 of	 distribution	 of	MPAG;	 Q/F,	 apparent	 compartmental	
clearance	 between	 the	MPA	 central	 and	 peripheral	 compartments;	 Ka,	 absorption	
rate	 constant	 of	 MPA;	 K41,	 rate	 constant	 for	 biliary	 excretion	 and	 enterohepatic	
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